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Triple-negative breast cancer (TNBC), comprised predominantly of the basal-like 
(BBC) and claudin-low (CLBC) intrinsic subtypes, is a proliferative, invasive disease that 
accounts for 15-20% of breast cancer cases. Unlike with other breast cancer subtypes, 
TNBC treatment modalities are generally limited to surgery, radiation, and cytotoxic 
chemotherapy. Therefore, identification of molecular contributors to TNBC initiation and 
progression, including signals with relevance to the tumor microenvironment, is important for 
development of biologically targeted therapies.  
 It is well accepted that the tumor microenvironment, the non-cancerous cells and 
tissues in proximity to the frank cancer cells, plays a critical role in breast cancer initiation 
and progression. However, little is known about the evolution of stromal-epithelial 
communication during breast tumorigenesis, or how specific signaling mediators alter 
subtype-specific tumor behavior. To this end, this work leveraged a suite of model systems 
to better understand how specific components of TNBC microenvironments influence tumor 
phenotypes and stromal-epithelial interactions. Following a literature review in Chapter 1, 
Chapter 2 describes research that used three-dimensional culture models of a pre-invasive 
BBC cell line panel, together with novel imaging technology, to evaluate cancer cell-
fibroblast interactions during early stages of tumor initiation. Relative to wild-type cells, pre-
invasive BBC cells lacking the TP53 tumor suppressor gene exhibited accelerated and 
unique responses to fibroblast co-culture. In Chapter 3, the role of the immune 
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microenvironment in TNBC progression was evaluated using a novel animal model. Myeloid-
specific Glut1 knockout mice were used to demonstrate that alterations in myeloid cell 
metabolism reduced the inflammatory potential of mammary tissue macrophages (MTMs) 
and impeded CLBC progression. Chapter 4 leveraged observational studies of human tissue 
to develop a digital algorithm to identify histologically stained endothelial cells in cancer-
adjacent breast. This algorithm will be used in future studies to quantitatively characterize 
the vascular microenvironment both across breast cancer subtypes, and for TNBCs in 
particular. Finally, Chapter 5 integrates insights from all three investigations to identify future 
directions for studies of TNBC microenvironments. This work reveals previously 
uncharacterized relationships between TNBCs and their associated stromal cells, some of 
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Chapter 1 is a previously unpublished overview of breast cancer risk factors, 
molecular features, and microenvironmental constituents, particularly as they relate to triple-
negative breast cancers (TNBCs). All figures have been created for the express purpose of 
this chapter and have not previously appeared elsewhere.  
The study presented in Chapter 2 is a manuscript in preparation that explores how 
gene-microenvironment interactions influence epithelial phenotypes and gene expression 
patterns associated with TNBC carcinogenesis. As lead author, I conceptualized the study, 
designed experiments, and analyzed all data reported in this document. Optical coherence 
tomography was performed in collaboration with Lin Yang, PhD and Xiao Yu, PhD; related 
financial and materials support was provided by Amy Oldenburg, PhD. Microarrays were run 
by the staff of the Lineberger Comprehensive Cancer Center Genomics Core Facility. Jason 
Pirone, PhD assisted with deconvolution of co-culture gene expression data, and Melissa 
Troester, PhD provided additional intellectual input, as well as financial and materials 
support. Finally, Rupninder Sandhu, PhD, designed and performed additional microarray 
experiments that will appear in the final document submitted for publication. 
Chapter 3 discusses how alterations in macrophage glucose metabolism modulate 
mammary gland inflammation and TNBC progression in a murine model. It also identifies 
novel macrophage phenotypes that may be important in TNBC biology. This study is 
approaching re-submission and has been reformatted from its original version in accordance 
with university dissertation formatting requirements. Please note that the text presented 
herein will likely deviate from the final published form. Co-authors include Alyssa J. Cozzo, 
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Alex J. Freemerman, J. Ashley Ezzell, Joseph A. Galanko, Stephen D. Hursting, Melissa A. 
Troester, and Liza Makowski. 
Chapter 4 describes the development of a novel digital algorithm designed to 
quantitate CD31 immunohistochemical staining (vascular endothelial cells) in cancer-
adjacent, histologically benign human breast tissue. This algorithm will ultimately be used to 
investigate how patterns of endothelial cell marker distribution relate to breast cancer 
subtype, known breast cancer risk factors, and other histologic tissue features. Co-authors 
on this manuscript will include Linnea Olsson, Bentley R. Midkiff, Kirk K. McNaughton, J. 
Ashley Ezzell, Erin L. Kirk, and Melissa Troester.  
Chapter 5 is an integrative summary of the data presented in Chapters 2, 3, and 4. It 
also describes ongoing analyses and identifies future directions for studies of TNBC 
microenvironments. Finally, due to substantial redundancy among chapters, a single list of 
references can be found at the end of this dissertation. Please note that ref. 183 is an 
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1.1. Normal mammary gland development, anatomy, and histology: a précis 
  
The normal mammary gland is a complex, dynamic structure that undergoes 
numerous anatomic and functional changes throughout life [1]. Initial stages of mammary 
gland development occur during the pre-natal period, wherein ectodermal bud cells 
embedded within the mammary mesenchyme proliferate and invade into the mammary fat 
pad to form a small ductal epithelial tree [2]. Unlike most other organs, remaining stages of 
mammary gland development occur postnatally. During puberty, inductive hormonal and 
growth factor-derived signals stimulate extensive elongation and lateral branching of the 
nascent epithelial tree, and promote the differentiation of contractile myoepithelial cells [3]. 
This mature, adult breast tissue can undergo further differentiation during later life stages 
such as pregnancy and lactation, culminating in the formation of a milk-producing, lobulo-
alveolar compartment [1, 2]. Following the cessation of lactation, the process of involution 
returns the parous mammary gland to a pre-pregnancy-like morphology via the activation of 
highly regulated developmental and wound-healing pathways [4, 5]. 
 In adult women, the breast contains 15-25 secretory lobes that are embedded within 
stromal (connective) tissue and arranged radially around the nipple (Figure 1.1A). Each 
lobe is comprised of 20-40 glandular lobules (also known as terminal ductal lobular units 
[TDLUs]), which constitute the functional (i.e., milk-producing) acinar units of the mammary 
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gland (Figure 1.1A-B). Histologically, the mammary gland is composed of an outer layer of 
contractile myoepithelial cells and an inner layer of cuboidal to columnar luminal epithelium; 
this latter cell type can be further sub-divided into secretory lactocytes and non-secretory 
ductal cells [6, 7]. Importantly, the epithelial and stromal compartments of the breast are 
separated by a laminin-rich basement membrane (Figure 1.1C) [8]. 
 
 
1.2. Overview of breast cancer incidence and mortality 
 
Breast cancer predominantly arises from the luminal ductal epithelial cells of the 
mammary TDLU [8] and is the most common non-cutaneous malignancy among women in 
the United States (US). Breast cancer is also the second-leading cause of cancer-related 
mortality in this population, with an estimated 266,120 new cases and 40,920 deaths 
anticipated in 2018 [9]. According to 2010-2014 Surveillance, Epidemiology, and End 
Results Program (SEER) data, breast cancer in the US is most frequently diagnosed among 
women aged 55-64 (median age at diagnosis: 62 years; seer.cancer.gov), although the 
median age at diagnosis is lower for African American than Caucasian women (59 vs. 63 
years; www.cancer.org). Indeed, race is an important determinant of breast cancer risk and 
mortality. Among all breast cancer cases, breast cancer incidence from 2010-2014 was 
higher in Caucasian and African American women than in any other racial or ethnic group 
(128.7 and 125.5 cases/100,000 women, respectively; www.cancer.org). However, African 
American women have the highest breast cancer incidence rates prior to the age of 40, and 






1.3. Breast cancer subtypes 
 
Beginning in the early 2000s, a molecular taxonomy of “intrinsic” breast cancer 
subtypes (luminal A, luminal B, human epidermal growth factor [HER2]-enriched, basal-like 
[BBC], and claudin-low [CLBC]) was identified on the basis of tumor gene expression 
patterns. These subtypes were found to differ substantially with respect to tumor molecular 
features, risk factors, treatment responses, and patient outcomes [10-16]. A sixth intrinsic 
subtype, normal-like breast cancer, is now believed to reflect contamination of tumor RNA 
with that of surrounding normal breast tissue [17]. Surrogate immunohistochemical (IHC) 
markers, including the estrogen receptor (ER), progesterone receptor (PR), and HER2, are 
routinely used to identify breast cancer subtypes in clinical settings; however, it should be 
noted that IHC-based and intrinsic subtype designations do not completely converge [18]. 
Nevertheless, luminal A and luminal B breast cancers (herein referred to as “luminal” 
cancers unless otherwise specified) are generally ER+/PR+, whereas basal-like and claudin-
low tumors are typically negative for all three IHC-based biomarkers (ER-/PR-/HER2-; so-
called “triple-negative” breast cancers [TNBCs]). Interestingly, recent publications have 
reported that the utilization of additional IHC markers, including HER1, epidermal growth 
factor receptor (EGFR), and/or cytokeratin 5/6 (CK5/6), can facilitate diagnoses of BBC 
more specifically [19-23]. In fact, a five-marker IHC panel consisting of ER, PR, HER2, 
EGFR, and CK5/6 has been shown to predict BBC patient survival more accurately than the 
original triple-negative phenotype [20].  
The focus of this dissertation research is triple-negative breast cancer. As described 
below, TNBC is characterized by poor clinical outcomes relative to other breast cancer 
subtypes, and exhibits molecular features that preclude effective utilization of currently 
available biologically targeted therapies. A better understanding of TNBC biology at all 
stages of disease is critical for improving patient outcomes  
 
 4 
1.4. Features of triple-negative breast cancers 
 
Triple-negative breast cancers exhibit unique risk factor profiles, molecular features, 
and clinical behaviors in comparison to other breast cancer subtypes. In this section, the 
clinical and molecular properties of human TNBCs (defined by the three-marker IHC profile), 
as well as those of BBCs more specifically, will be described in detail. Features of human 
CLBCs will also be presented in accordance with data availability; however, it should be 
noted that substantially less is known about CLBCs relative to the remaining intrinsic 
subtypes. 
 
1.4.1. Risk factors  
Age and race: Triple-negative breast cancers account for approximately 15-20% of 
all breast cancer cases in the general population, but are more prevalent among pre-
menopausal and African American women [19, 22]. Specifically, compared to luminal A 
cases, patients with BBC (defined as ER-/PR-/HER2-/HER1+, and/or CK5/6+) were 2.1 times 
more likely to be African American [19, 22], and 4.5 times more likely to be younger than 40 
years of age [22]. Moreover, prevalence estimates indicated that BBC was significantly more 
prevalent in pre- compared to post-menopausal African American women (39% and 14%, 
respectively), as well as non-African American women of any age (16%), even after 
adjustment for tumor stage at diagnosis [19]. Similarly, a study of a racially heterogeneous 
population found that, compared to women of any other racial or ethnic group, African 
American women were 3 times more likely to present with TNBCs irrespective of age [24].  
 Obesity status: The relationship between obesity and breast cancer is controversial, 
as positive, negative, and null associations have been reported in the literature [25]. 
However, accumulating evidence indicates that obesity is associated with increased risk of 
TNBC, particularly among young/pre-menopausal women. For example, a pooled analysis 
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of 35,568 cases from the Breast Cancer Association Consortium revealed that, among 
women <50 years of age, obese women (defined as having a body mass index [BMI] >30 
kg/m2) were 1.8 times more likely to present with triple-negative (defined as ER-/PR-/HER2-) 
compared to ER+/HER2- or PR+/HER2- tumors [26]. Similarly, data from the Seattle-Puget 
Sound SEER cancer registry indicated that obesity was associated with a 1.3-fold elevated 
risk of TNBC among women of all ages, and that risk of TNBC, but not non-TNBC, was 
further elevated among younger women aged 41-45 (odds ratio [OR]: 2.2; 95% confidence 
interval [CI]: 0.9-5.24) [27].  
In addition to positive associations between obesity and ER-/PR-/HER2- TNBC, 
relationships between obesity and BBC have also been described. For instance, compared 
to patients with luminal A tumors, BBC patients were 3.75-fold more likely to be highly obese 
(BMI >35 kg/m2) than normal weight (BMI 18.5-24.9 kg/m2) [28]. Additionally, in the Carolina 
Breast Cancer Study (CBCS), a population-based study that oversampled for younger (<50 
years of age) and African American women, an elevated waist-hip ratio (WHR) was strongly 
associated with BBC in both pre- and post-menopausal women [22]. Interestingly, BMI was 
not associated with BBC in this study [22], consistent with views that WHR is a superior 
metric of adiposity given that it better reflects important considerations such as adipose 
tissue distribution (e.g. central/abdominal vs. peripheral) [29, 30]. 
 Reproductive history: It is well established that early menarche, nulliparity, late age 
at first birth, and never having breastfed are associated with an increased risk of breast 
cancer. As such, recent studies have sought to establish whether these reproductive 
variables are also associated with increased TNBC risk. Increased duration of breastfeeding 
is the single reproductive factor most consistently associated with reduced risk of both 
TNBC and BBCs more specifically [22, 31, 32]. Interestingly, this association has been 
shown to be modified by age and race, as parous African American women between 20 and 
44 years of age who breastfed for at least 6 months had an 82% lower TNBC risk than 
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parous African American women who had never breastfed [32]. In addition, an inverse 
association between age at menarche and TNBC/BBC risk has been reported in a small 
number of studies [22, 33, 34]. However, both parity and younger age at first birth have 
been inconsistently associated with TNBC risk, with certain studies reporting positive 
associations [22, 33, 35, 36], and others failing to reach statistical significance [reviewed in 
31].  
 
1.4.2. Clinical presentation 
 Triple-negative breast cancers present as palpable tumors in the majority of patients, 
likely due to the reduced rates of mammographic screening in younger and African 
American women compared to older and Caucasian women, respectively [37]. These 
cancers also frequently present as high grade, high stage, and highly mitotic lesions; are 
poorly differentiated in approximately 90% of cases [19, 37]; and are characterized by 
geographic patterns of necrosis, strongly demarcated “pushing borders” of invasion, and 
conspicuous lymphocytic infiltrates [21]. 
 
1.4.3. Molecular features 
 Basal-like subtype: Basal-like breast cancers are more molecularly homogeneous 
than TNBCs classified according to the three-marker IHC panel (i.e., ER-/PR-/HER2- 
tumors), and were first described in the late 1980s using IHC data collected from benign and 
malignant breast tissue specimens [38, 39]. These tumors were designated “basal-like” due 
to their expression of cytoskeletal proteins associated with the basal (myoepithelial) layer of 
the normal mammary gland, including CK5/6, CK14, and vimentin [21, 23, 38-40]. At the 
genomic level, BBCs are also enriched for a “basal-like” gene cluster, consisting of growth 
factor receptors such as MET (cMET), EGFR, and KIT (cKIT); cytoskeletal elements such as 
CAV1 and CAV2 (caveolins 1 and 2) and CDH3 (p-cadherin); and the gene encoding the 
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small heat shock protein, αB-crystallin (CRYAB), among others [41]. However, it is important 
to note that BBCs do not originate from the myoepithelium despite their similarities to this 
cell type. Instead, elegant genetic studies in murine models have suggested that these 
tumors, or at least a subset thereof, are derived from mammary luminal epithelial 
progenitors [42]. 
In accordance with their highly mitotic behavior, BBCs exhibit genetic defects that 
accelerate cellular proliferation and undermine cell stress responses. Most notably, >80% of 
these tumors harbor mutations in TP53 (tumor protein 53; p53) [19, 43], a master regulator 
of genome stability. Importantly, compared to luminal breast cancers wherein missense 
TP53 mutations predominate in approximately 12-35% of cases, BBCs are substantially 
enriched for deleterious nonsense (truncation), frameshift, and splice-site mutations that 
severely impair p53 protein function [43, 44]. In fact, although p53-wild-type (WT) BBCs 
have been reported in the literature, an analysis of genetic signatures of inferred p53 
pathway activity in 506 breast tumors revealed that loss of p53 pathway function may be a 
feature of most, if not all, BBCs [43]. Future research should address the impact of specific 
TP53 mutation types on therapeutic responses and patient survival, particularly in 
association with tumor subtype and other prognostic clinicopathologic characteristics.  
In addition to exhibiting unique TP53 mutation profiles, BBCs are also strongly 
associated with germline mutations in the tumor suppressor gene BRCA1, a critical 
component of the DNA double-strand break (DSB) repair pathway. Indeed, Foulkes et al. 
demonstrated that tumor-specific expression of CK5/6 (i.e., a “basal-like” epithelial 
phenotype) was significantly associated with the presence of BRCA1 germline mutations 
[45], whereas Sorlie et al. found that 100% of tumors from BRCA1 mutation carriers fell 
within the basal-like intrinsic subtype [46]. Interestingly, with the recent development of 
experimental poly(ADP-ribose) polymerase (PARP) inhibitors, the association between 
germline BRCA1 mutations and BBCs now has important clinical implications, with the 
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combination of BRCA1 loss-of-function and PARP inhibition inducing synthetic lethality in 
cancer cells [47]. 
 Claudin-low subtype: First reported in 2007, CLBC is the most recently identified 
intrinsic breast cancer subtype. Early genomic studies of 13 human claudin-low tumors, 12 
of which were ER-, indicated that these lesions exhibited low expression levels of tight 
junction proteins such as CLDN3, CLDN4, and CLDN7 (hence, “claudin-low”), and high 
expression levels of lymphocyte and endothelial cell markers [48]. Further work has 
revealed both similarities and differences between claudin-low and basal-like tumors. For 
example, like BBCs, CLBCs are more likely to present as large (>2 cm), high-grade, 
undifferentiated lesions with circumscribed borders [49]. In contrast to basal-like tumors, 
however, CLBCs are characterized by a mesenchymal morphology and are genomically 
enriched for markers of cancer stem cells and the epithelial-mesenchymal transition [12, 50]. 
CLBCs are also more likely than BBCs to be ER+ or non-triple-negative [50, 51], indicating 
the potential for greater heterogeneity among claudin-low relative to basal-like tumors [51]. 
 
1.4.4. Prognosis and clinically available treatment modalities 
Due in part to the highly proliferative nature of TNBCs, these tumors exhibit more 
favorable responses to cytotoxic chemotherapy than ER+ and HER2+ cancers, particularly in 
the neoadjuvant (pre-operative) setting [52-54]. Indeed, the cytotoxic agents used in the 
treatment of TNBCs, such as fluorouracil, alkylating agents (e.g., cyclophosphamide), 
anthracyclines (e.g., doxorubicin; epirubicin), and taxanes (e.g., paclitaxel; docetaxel) non-
specifically target actively dividing cells; hence, it follows that highly mitotic TNBC cells 
would exhibit greater susceptibility to these drugs than more indolent (i.e., luminal) cancers. 
Accordingly, significantly higher rates of pathologic complete response (pCR; defined as a 
lack of histologic evidence of residual invasive cancer cells following neoadjuvant 
chemotherapy) have been observed in TNBC compared to non-TNBC patients [53, 55]. 
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Further, among cases achieving pCR, no survival differences have been reported in 
association with tumor subtype within the first ~5-6 years of follow-up [53, 56]. Interestingly, 
in one study of 5447 clinically annotated breast cancers, expression of a proliferation-related 
metagene in claudin-low tumors was significantly lower than in BBCs, but significantly higher 
than in luminal A tumors [51]. Thus, although this study did not detect significant differences 
in disease-free survival between CLBC and BBC patients within the first 10 years of follow-
up [51], more comprehensive evaluations of long-term CLBC patient survival is an important 
avenue of future research.  
Despite their relatively increased neoadjuvant chemosensitivity, TNBCs for which 
pCR is not achieved are paradoxically more likely than other breast cancer subtypes to 
locally recur and/or distantly metastasize – particularly to visceral organs and the central 
nervous system – within the first 3 to 5 years of patient follow-up [52, 53, 57, 58]. These 
observations illustrate the need to develop novel treatments that improve the progression-
free and overall survival of TNBC patients, particularly for those with residual disease (i.e., 
non-pathologically complete responders) following neoadjuvant therapy. 
 
 
1.5. The tumor microenvironment: Concepts, model systems, and constituents 
 
One possible explanation for the relatively increased rates of TNBC recurrence 
pertains to the concept of the “tumor microenvironment” or “tumor stroma,” the collection of 
non-cancerous cell and tissue types within (intratumoral microenvironment) and surrounding 
(extratumoral or cancer-adjacent microenvironment) a frank cancer. While the normal tissue 
microenvironment is indispensable for maintenance of tissue homeostasis and repression of 
tumorigenesis, evolving stromal-epithelial interactions in the context of cancer exert 
profound tumor-promoting effects [59]. In this section, experimental model systems used to 
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study stromal-epithelial interactions in breast cancer, as well as the advantages and 
disadvantages thereof, will be discussed. Specific constituents of the tumor 
microenvironment germane to this dissertation research, including fibroblasts, macrophages, 
and endothelial cells, will also be described as they relate to TNBCs. 
  
1.5.1. Model systems for studies of the tumor microenvironment 
 In vitro co-culture models: Cancer cell lines cultured in vitro on plastic dishes 
(“monocultures”) are perhaps the most ubiquitous models used to study genetic and 
molecular aberrations associated with tumor initiation and progression. Indeed, extensive 
work has been undertaken to comprehensively characterize the molecular features, 
including intrinsic subtypes, of over 50 breast cancer cell lines [60]. However, these models 
are only informative of cancer cell-intrinsic defects, and cannot be used to explore 
microenvironmental influences on cancer cell biology.  
In response to the limitations of cancer cell monocultures, two-dimensional (2D) co-
culture models have been developed to enable studies of stromal-epithelial interactions. 
These highly tractable model systems consist of two (or more) cell types grown either in 
direct physical contact (“direct” co-cultures; Figure 1.2A) or separated by a “transwell,” a 
porous physical barrier that enables cellular communication exclusively via soluble signaling 
mediators (Figure 1.2B). Although both types of 2D co-culture models have shown utility in 
gene expression studies [reviewed in 61], transwell cultures are particularly useful for 
evaluating the influence of the microenvironment on cancer cell phenotypes such as 
proliferation, migration, and invasion [62]. Importantly, however, 2D co-culture models 
exhibit limited physiological relevance, because: 1) rigid culture substrates, such as plastic 
and glass, exhibit substantially greater mechanical stiffness than even the stiffest living 
tissue [63]; and 2) the morphologic and organizational features of cells in 2D culture do not 
emulate in vivo conditions due to the loss of important contextual signals [64].  
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 To study stromal-epithelial interactions in a more tissue-relevant environment, three-
dimensional (3D) co-cultures can be used. Several variations of this model have been 
reported in the literature [reviewed in 62]; however, one of the most widely used variations is 
the “spheroid” or “organoid” culture, wherein breast epithelial cells suspended in a 3D 
collagen- and laminin-rich extracellular matrix (ECM) form polarized, multi-cellular structures 
that closely recapitulate the in vivo architecture of mammary gland secretory acini [65, 66] 
(Figure 1.2C-D). Over the last 3 decades, pioneering work has demonstrated that the ECM 
plays a critical role in maintaining tissue integrity by imparting both structural support and 
mechanosignaling cues to surrounding epithelia (for an excellent comprehensive review that 
provides a historical perspective on the utility of 3D cultures to studies of the tumor 
microenvironment, refer to ref. [67]). Thus, 3D co-cultures represent powerful tools with 
which to study normal stromal-epithelial communication patterns “in context”, and to 
understand how these interactions change in the setting of malignancy. However, one 
challenge associated with the use of 3D co-cultures is the limited number of techniques that 
can quantitatively assess alterations in organoid phenotypes. Development of novel 
analytical approaches, particularly in the realm of biomedical imaging, is an active area of 
current research [68-71] (see also, Chapter 2). 
In vivo murine models: Utilization of murine models facilitates a comparative biology 
approach to studies of the tumor microenvironment. Two of the most widely used types of 
murine models include orthotopic models, wherein murine cancer cells are orthotopically 
injected into syngeneic mice, and xenograft models, in which human cancer cells are 
heterotopically implanted into immunocompromised animals. However, these models 
possess certain limitations: Orthotopic tumors do not mimic many of the etiologic and/or 
molecular features of human tumors, whereas xenograft tumors do not develop in the 
context of an immunocompetent human microenvironment, precluding analyses of how 
stromal-epithelial interactions influence the course of human disease [72]. In contrast, 
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genetically engineered mouse models (GEMMs), wherein expression of a given gene can 
be spatially and/or temporally controlled, can more closely recapitulate specific aberrations 
found in human tumors. In fact, recent genomic expression analyses have identified GEMM 
“counterparts” to human breast cancer intrinsic subtypes [73]. For example, mammary 
tumors from three mouse lines, including the Tg (transgenic) C3(1)-Tag, TgWAP-Myc, and 
Trp53-/- (p53-null) lines, cluster with human BBCs [73], suggesting that these models may be 
particularly useful for studies of basal-like microenvironments. Interestingly, a single GEMM 
analogous to human CLBC was not identified in this study; instead, the gene expression 
patterns of unique tumors from multiple GEMMs converged to form a claudin-low expression 
class [73]. Nevertheless, two additional GEMMs that closely mimic the genomic expression 
patterns of human CLBC have been described, including: 1) orthotopic, syngeneic, 
transplantable tumors from a Trp53-/- mouse (T11 model) [73, 74]; and 2) transgenic 
mammary-specific Met-overexpressing mice harboring a conditional loss of Trp53, also in 
the mammary epithelium [75].  
Cancer-adjacent normal tissue: Studies of cancer-adjacent normal (CAN) breast 
tissue can reveal important associations between tumor biology and features of extra-
tumoral microenvironments as they relate to breast cancer subtypes. In particular, given that 
TNBCs are more likely than other subtypes to locally recur within the first 3 to 5 years of 
patient follow-up [52, 53, 57, 58], these studies may yield important insights into 
microenvironmental factors that contribute to subtype-specific differences in disease 
recurrence. Accordingly, recent work has shown that the genomic expression patterns of 
CAN breast tissue differ in association with the intrinsic subtype [76] or ER status [77] of the 
corresponding tumor. Studies of CAN tissue have also identified extra-tumoral gene 
signatures that predict mortality among ER+ cases [78], as well as in “whole tumor” datasets 
independent of subtype [79], or ER or HER2 status [80]. However, given that these studies 
have primarily focused on global CAN tissue gene expression patterns, future work should 
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examine associations between tumor clinicopathologic factors and specific components of 
the extra-tumoral microenvironment, particularly in the context of TNBCs (see also, Chapter 
4). 
 
1.5.2. Cellular constituents of TNBC microenvironments 
Fibroblasts: Fibroblasts are a major stromal cell component of many normal tissue 
types, including breast, and primarily function in the production and secretion of ECM, as 
well as the regulation of epithelial cell differentiation and polarity [81]. In the setting of 
cancer, however, numerous studies suggest that dysregulated fibroblasts (also known as 
cancer-associated fibroblasts [CAFs]) facilitate tumor progression by promoting ECM 
remodeling, inflammation, angiogenesis, and tumor cell proliferation [reviewed in 81]. 
Indeed, both high mammographic density (a radiologic metric of fibroglandular breast 
content) and a high histologic stroma-tumor ratio are negative prognostic indicators in breast 
cancer, particularly among TNBCs and ER- tumors, respectively [82-84]. 
Little is known about fibroblast-epithelial interactions as they relate to breast cancer 
subtypes. However, one study by Camp et al. [85] revealed that stromal-epithelial 
communication patterns are distinct in co-culture models of basal-like vs. luminal breast 
cancer. Specifically, fibroblast-luminal co-cultures upregulated genes involved in a number 
of cellular proliferation pathways, whereas fibroblast-BBC co-cultures upregulated genes 
associated with immune signaling and wound healing responses. Consistent with this gene 
expression data, basal-like, but not luminal, breast cancer cells also exhibited enhanced 
migratory and wound-healing capacities in response to fibroblast co-culture [85]. 
Interestingly, primary fibroblasts isolated from the interface zone of human TNBCs were also 
shown to induce the epithelial-mesenchymal transition (EMT) in a TNBC cell line [86]. 
However, as this study did not evaluate the effect of fibroblasts on luminal breast cancer 
cells phenotypes [86], it is unclear whether the observed induction of EMT in TNBC cells is a 
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subtype-specific phenomenon, or rather a general cellular response to interface-zone 
fibroblasts from triple-negative tumors. 
In addition to enhancing the invasive potential of TNBC cells, a growing body of work 
indicates that CAFs may also influence the therapeutic responses of this tumor subtype. For 
example, fibroblast-specific secretion of the pleiotropic signaling molecule hepatocyte 
growth factor (HGF) has been recently shown to mediate TNBC cell resistance to EGFR 
tyrosine kinase inhibitors; these data offer a possible explanation as to why EGFR-over-
expressing TNBCs fail to respond to drugs in this class [87]. Interactions between CAFs and 
stromal immune cells may also facilitate TNBC progression and impede therapeutic 
responses by fostering an immunosuppressive microenvironment. One study of CAF 
heterogeneity determined that a specific subset of CAFs (“CAF-S1,” defined as CD29Med 
FAPHi [fibroblast activation protein] FSP-1Low-Hi [fibroblast-specific protein-1] αSMAHi [alpha-
smooth muscle actin] PDGFRβMed-Hi [platelet-derived growth factor receptor beta] CAV1Low) 
were enriched in the microenvironment of human TNBCs relative to other tumor subtypes, 
and were associated with the stromal infiltration of immunosuppressive, regulatory FOXP3+ 
(forkhead box P3) T cells [88]. The CAF-S1 subpopulation also promoted the differentiation 
of FOXP3+ T cells in the tumor microenvironment, and enhanced their capacity to inhibit the 
proliferation of pro-inflammatory effector T cells [88]. Additionally, xenograft models in which 
primary human monocytes were co-transplanted with TNBC or luminal cell lines revealed 
that CAFs in triple-negative microenvironments produce CXCL16 (chemokine C-X-C motif 
ligand 16), in turn recruiting both additional CAFs and immunosuppressive myeloid cells 
[89]. Taken together, these studies suggest that CAFs may be a viable therapeutic target in 
triple-negative tumors, as well as a potential biomarker of therapeutic responses. 
Accordingly, targeting of CAFs with the anti-fibrotic agent Perfenidone inhibited CAF-
induced TNBC morphogenesis in 3D culture models, and synergistically blocked tumor 
growth and lung metastasis when administered in combination with doxorubicin [90]. 
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Macrophages: Macrophages are a highly heterogeneous class of myeloid-lineage 
cells that function in both developmental and immune response processes [91-94]. In the 
context of breast cancer, however, these cells have been implicated in numerous facets of 
tumor progression, including the induction of angiogenesis (see below) [95, 96]; 
immunosuppression and tumor immune evasion [97]; and local invasion and metastasis [98-
100]. Accordingly, it is unsurprising that tumor-associated macrophage (TAM) infiltration into 
the breast cancer microenvironment is associated with triple-negativity [101-103], and 
correlates with an increased risk of metastasis and reduced recurrence-free survival among 
these patients [101-104]. Elucidation of specific TAM-TNBC interactions that promote tumor 
progression warrants further study. 
In addition to the effects of TAM infiltration on tumor biology, reciprocal interactions 
between macrophages and breast cancer cells can also exert striking alterations in 
macrophage phenotypes. Historically, macrophages have been classified as either M1 (pro-
inflammatory, classically activated) or M2 (anti-inflammatory/immunosuppressive, 
alternatively activated) cells; however, this dichotomy is insufficient to account for the 
diversity and plasticity of macrophages in vivo [reviewed in 25]. In the setting of breast 
cancer, TAMs exhibit properties of both M1 and M2 cells, and molecularly distinct 
subpopulations have been identified in association with their locations relative to the frank 
tumor. For example, migratory, pro-metastatic “M1-like” TAMs are generally observed in 
perivascular regions, whereas sessile, pro-angiogenic, “M2-like” TAMs are more prevalent in 
hypoxic regions and at the tumor-stroma interface [105]. Interestingly, breast cancer 
subtypes exhibit differential abilities to “educate” macrophages toward TAM phenotypes. For 
example, exposure to conditioned culture medium from claudin-low, but not luminal, breast 
cancer cells facilitated the differentiation of peripheral blood mononuclear cells into 
immunosuppressive M2-like macrophages, in a mechanism dependent upon CLBC-
mediated secretion of macrophage colony-stimulating factor (M-CSF) [106]. Similarly, basal-
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like, but not luminal, breast cancer cells stimulated the differentiation of THP-1 monocytes 
into a “mixed” population of M1- and M2-like macrophages, with some cells displaying dual 
positivity for both M1 and M2 markers, and others exclusively expressing markers 
associated with a single subpopulation [107]. Further refinement of TAM phenotypes in 
TNBC microenvironments, as well as the prognostic and potential therapeutic implications 
thereof, is an important avenue for future research. 
Endothelial cells: The process of angiogenesis, or the formation of new blood 
vessels from existing vasculature, is a critical, rate-limiting step of tumor growth and 
metastasis. Establishment of a tumor vascular supply occurs in a discrete step known as the 
“angiogenic switch,” wherein the net balance of pro- and anti-angiogenic signaling mediators 
favors blood vessel development [108]. Recent reports have shown that high microvessel 
density (number of vessels per unit area) and microvessel proliferation (number of vessels 
containing Ki67+ endothelial cells) are associated with both BBCs [109, 110] and specific 
molecular features of basal-like tumors (e.g., CK5/6, p-cadherin, or EGFR protein 
expression). These data indicate that a specific subset of TNBC patients may have strong 
potential to benefit from anti-angiogenic therapies [109, 110].  
Examination of cancer cell-endothelial interactions is crucial for better understanding 
how the vasculature contributes to the growth, invasion, and metastasis of TNBCs. For 
example, Ingthorsson and colleagues [111] recently demonstrated that primary endothelial 
cells derived from reduction mammoplasty tissue stimulated the growth and 3D 
morphogenesis of both pre-invasive and malignant TNBC organoids. Two-dimensional co-
culture models were subsequently used to show that the endothelial-derived proliferative 
signals were soluble in nature; however, specific signaling mediators responsible for the 
observed phenotypes were not identified [111]. Using a similar model system, this same 
group also showed that reduction mammoplasty-derived endothelium could induce the 
epithelial-mesenchymal transition (EMT) in “stem-like” (CD44hi/CD24low) BBC cells, and that 
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this process could be partially reversed via inhibition of HGF signaling [112]. With respect to 
TNBC metastasis, Di Modica et al. [113] demonstrated that TNBC cells release exosomes 
containing miR-939, a microRNA molecule that inhibits translation of the endothelial cell 
adherens junction protein, vascular endothelial (VE)-cadherin. Notably, miR-939-mediated 
targeting of VE-cadherin compromised the integrity of endothelial cell-cell contacts, and 
facilitated TNBC cell trans-endothelial migration, a critical step in the metastatic cascade. 
CLBC cells have been further shown to secrete plasminogen activator inhibitor-1 (PAI-1), a 
mesenchymal marker of EMT that stimulates the production of chemokine (C-C motif) ligand 
5 (CCL5) by endothelial cells [114]. In turn, endothelial-derived CCL5 accelerates TNBC-
mediated PAI-1 secretion, and promotes CLBC cell migration, invasion, and metastasis 
through the formation of a positive feedback signaling loop [114]. Taken together, in light of 
the fact that currently available angiogenesis inhibitors do not confer a significant survival 
advantage to TNBC patients [115], this body of work suggests that the study of cancer cell-
endothelial communication patterns may be a powerful means by which to identify novel 
anti-angiogenic targets for TNBC.  
Little is known about the endothelium of TNBC-adjacent breast. Moreover, very little 
work has examined the vascular properties of normal (i.e., non-cancer-associated) 
mammary tissue. One study of an unspecified number of reduction mammoplasty tissue 
samples revealed that CD31+, VE-cadherin+, and CD34+ microvessels are prominent 
features of TDLUs [116]. In another study of reduction mammoplasty tissue from 9 pre-
menopausal women, Naccarato et al. [117] described different patterns of microvascular 
distribution and morphology in breast ducts vs. TDLUs: whereas ducts were surrounded by 
a relatively higher number of small, prototypical capillaries, TDLUs were encompassed by a 
relatively smaller number of large microvessels that were sinusoidal in shape. The functional 
significance of these findings in normal tissue, as well as whether similar features are also 
apparent in TNBC-adjacent breast, is currently unknown.  
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1.6. Benign and pre-malignant breast lesions: Role of microenvironment in 
progression to invasive disease 
  
Over the last several decades, a spectrum of benign and pre-malignant breast 
disorders with varying pre-cancerous potentials have been identified and characterized. By 
definition, these lesions are distinct from frank breast cancers, in that the former are 
confined to the mammary gland proper and do not breach the epithelial basement 
membrane. In this section, the features of benign and pre-malignant growths germane to 
this dissertation will be briefly discussed, with emphases on: 1) their associations with 
invasive breast cancer risk; and 2) mechanisms by which tissue microenvironments regulate 
the transition from pre-invasive to malignant disease. 
 
1.6.1. Clinical and histologic features and associated breast cancer risk 
Fibrocystic change: Formerly known as “fibrocystic disease,” fibrocystic change is a 
heterogeneous class of common, benign disorders that are most prevalent in pre-
menopausal women under the age of 50 [118]. These lesions may be proliferative (e.g., 
hyperplasia without atypia; intraductal papilloma) or non-proliferative (e.g., cysts) [6, 118], 
and are thereby associated with differential risks of invasive breast cancer. For example, two 
large cohort studies with median follow-up times of 15 and 17 years, respectively, 
demonstrated that women with non-proliferative findings were not at increased risk of breast 
cancer [119, 120]. In contrast, women presenting with hyperplasia without atypia had a 1.9-
fold increased breast cancer risk compared to women with non-proliferative lesions [120], 
and a 1.88-fold increased risk relative to the expected number of breast cancer cases on the 
basis of Iowa SEER registry data [119]. Moreover, given that invasive breast cancer can 
occur co-incidentally with a benign lesion (for example, fibrocystic changes may occur 
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secondary to a proximal malignancy), mammographic and histopathologic evaluation of 
benign disorders is critical for an exclusionary diagnosis [6]. 
 Atypical ductal hyperplasia: Atypical ductal hyperplasia (ADH) is a proliferative 
epithelial abnormality that is typically diagnosed as an incidental finding, accounting for only 
~4% of symptomatic, non-malignant biopsies [121]. This disorder is characterized by the 
filling and distention of mammary ducts by a homogenous, proliferative population of 
dysplastic epithelial cells [119, 121], and is considered a bona fide pre-malignant condition 
because it exhibits some, but not all, features of invasive breast cancer [122]. Beginning in 
the mid-1980s, several studies have demonstrated that ADH is associated with an increased 
risk of subsequent invasive breast cancer, with a cumulative breast cancer incidence of 
approximately 30% after 25 years of follow-up [119-125]. However, with the exception of 
young age [119, 122, 126, 127], specific, uncontested demographic factors that predispose 
ADH patients to malignant disease have not been identified.  
Ductal carcinoma in situ: Pure ductal carcinoma in situ (DCIS) (i.e., DCIS in the 
absence of coincident invasive breast cancer) accounts for 20-25% of all newly diagnosed 
breast cancer cases in the US, and the incidence in women under 50 years of age only 
continues to rise in association with screening [128]. Similar to ADH, DCIS lesions are 
characterized by a homogeneous-appearing population of proliferative malignant epithelial 
cells, with no evidence of invasion beyond the basement membrane [121]. Accordingly, 
there is currently no clear consensus on the specific histologic criteria that should be 
employed to distinguish between ADH and DCIS: some clinicians apply a 2-mm size cutoff 
(<2 mm and >2 mm indicating ADH and DCIS, respectively), whereas others enumerate the 
number of involved ducts apparent on biopsy sampling (involvement of <2 acinar spaces 
indicative of ADH) [6, 129]. Interestingly, molecular studies have revealed that both IHC-
based and intrinsic subtype definitions of invasive breast cancer can also be applied to 
 
 20 
DCIS [130-134]. However, subtype frequencies may differ between DCIS and invasive 
cases [130-133]. 
DCIS is a known risk factor for invasive breast cancer; however, knowledge 
regarding the extent of this risk has shifted over time. For much of the 20th century, women 
diagnosed with DCIS were nearly universally treated with mastectomy [135]. However, given 
reports that lumpectomy and radiation were equally effective treatment strategies for 
invasive breast cancers, mastectomy rates for DCIS began to slowly decline beginning in 
~1980 [135]. According to current estimates, 25-50% of DCIS cases will recur as invasive 
cancers even in the absence of treatment (i.e., with biopsy alone), with latency periods of up 
to or greater than 40 years [136, 137]. However, clinically validated biomarkers and 
clinicopathologic features that predict DCIS progression to malignant disease remain elusive 
[138-140], indicating that the regulation of the invasive transition is an important area of 
future research (see below).  
 
1.6.2. Natural history and progression to invasive disease 
 The prevailing model of the pre-malignant to invasive breast cancer transition 
describes a stepwise, evolutionary continuum that was first conceptualized over 100 years 
ago [reviewed in 141]. First, initiating mutations within a luminal epithelial cell are believed to 
give rise to flat epithelial atypia, a disorder in which minimally proliferative, cytologically 
atypical luminal cells dilate the walls of the affected TDLU. The acquisition of growth-
promoting mutations, together with molecular alterations such as loss of heterozygosity 
(LOH) at hotspot tumor suppressor loci [141], is then believed to promote the development 
of ADH. In turn, a series of additional genetic and molecular changes (e.g., gene 
amplification [142]; further LOH events [143]) enables progression to DCIS, and potentially 
ultimately to invasive disease [141]. This clonal, linear model is supported by substantial 
evidence demonstrating that specific gene expression, histologic, and mutation patterns can 
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be detected in both pre-invasive and malignant breast tissue specimens from the same 
individual [144-148]. Several studies have similarly reported that transcriptional signatures 
unique to each stage of tumor progression are lacking, suggesting that the gene expression 
patterns required in the setting of malignancy are established at early stages of tumor 
development [139-141]. These observations, coupled with the inability to use molecular 
tumor data to identify DCIS lesions at risk of progression to malignant breast cancer, 
suggest that other factors, such as tissue microenvironments, are important regulators of the 
benign-to-invasive transition.  
No published reports have described microenvironmental features of flat epithelial 
atypia, and very little is known about those of ADH tissue. One study revealed that activated 
fibroblasts (defined as positive for both α-SMA and FSP-1) are present in the 
microenvironment of human ADH tissue (ADH-associated fibroblasts; AHFs), and possess 
an intermediate phenotype between that of normal- and cancer-associated fibroblasts [149]. 
These cells were also shown to enhance the proliferation of MCF-7 luminal breast cancer 
cells in transwell co-culture and tumor xenograft assays, in a mechanism dependent upon 
down-regulation of miR-200/c [149]. Whether AHFs can also promote growth of ADH 
epithelium and/or TNBC cells should be explored. Interestingly, an additional study 
demonstrated that HGF secretion was significantly up-regulated in co-culture models of 
basal-like ADH epithelium and fibroblasts, suggesting that HGF/cMET signaling is important 
in both pre-malignant [150] and invasive (see above) stages of BBC progression. 
In contrast, the role of the microenvironment in the regulation of the DCIS-to-invasive 
breast cancer transition has been more extensively evaluated. Broadly, recent studies have 
identified substantial genomic, phenotypic, and epigenetic changes between normal 
microenvironmental cells and their DCIS- and/or invasive cancer-associated counterparts, 
suggesting that these molecular alterations may promote progression to malignant disease 
[151-154]. Current research in this area has focused predominantly on fibroblasts and 
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myoepithelial cells, which have been shown to promote and inhibit the invasive transition, 
respectively. For example, Hu et al. used xenograft models to demonstrate that co-injection 
of a human DCIS cell line with either normal or cancer-associated fibroblasts promoted 
progression to invasive disease [155], potentially due to activation of cyclooxygenase-2 
(COX-2), a negative prognostic indicator in breast cancer [156]. Remarkably, the stimulatory 
effect of fibroblasts on DCIS xenograft invasion was abrogated by the additional injection of 
human myoepithelial cells [155]. Interestingly, the tumor-suppressive functions of this cell 
type have also been reported in other studies. For instance, normal myoepithelium 
constitutively expresses a number of proteinase inhibitors that both suppress cancer cell 
proliferation and prevent epithelial cell-mediated degradation of the basement membrane 
[152, 154, 157]. In fact, downregulation of these markers in DCIS-associated myoepithelium 
may promote the invasive transition by a variety of mechanisms, including: 1) activation of 
transforming growth factor beta (TGFβ) signaling; 2) reduced adhesion of myoepithelial cells 
to ECM proteins; and 3) increased secretion of matrix-degrading enzymes such as matrix 
metalloproteinases (MMPs) [154, 158, 159]. In sum, this body of work indicates that 
molecular studies of myoepithelial cells and/or fibroblasts in DCIS tissue samples may aid in 
the identification of patients at risk of progression from benign to invasive breast cancer. 
Future efforts to identify specific microenvironmental signaling mediators that may be 
relevant to this transition are paramount (see also, Chapter 2. 
 
 
1.7. Objectives and significance of this dissertation research 
 
 The diverse components of the breast cancer microenvironment are critical 
mediators of tumor initiation and progression. However, the molecular and histologic 
characteristics of tumor microenvironments as they relate to breast cancer subtypes remain 
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understudied. Therefore, the overarching goal of this research was to establish a foundation 
for understanding how tissue microenvironments vary in association with the subtype of the 
corresponding tumor, with a focus on clinically intractable TNBCs. In vitro, murine, and 
human tissue models were leveraged to profile diverse stromal-epithelial interactions in both 
pre-invasive and malignant TNBCs. Utilization of different models highlights the strengths of 
each system for studying particular endpoints relevant to TNBC microenvironments. 
Moreover, studying a variety of stromal cell types (fibroblasts, macrophages, and endothelial 
cells) underscores the complexity of the breast microenvironment. 
The primary objective of this work was to identify specific, microenvironmental 
signaling mediators with potential to influence TNBC initiation and progression (Chapters 2 
[fibroblasts] and 3 [macrophages]). In addition, to directly address the paucity of work 
relating to the vascular features of extra-tumoral microenvironments, Chapter 4 describes a 
novel digital algorithm that can be used to link vascular content and patterns of endothelial 
cell marker distribution in cancer-adjacent, histologically benign human breast tissue to 
epidemiologic data such as tumor subtype and known breast cancer risk factors. This work 
is significant because it reveals novel stromal-epithelial interactions in TNBCs. Molecular 
and histologic features unique to TNBC microenvironments may ultimately be leveraged as 
















A) Schematic representation of mammary gland gross anatomy in adult women. The 
mammary gland consists of secretory lobes that are connected to the nipple (grey arrow) via 
lactiferous ducts (black arrow). Lobes are further composed of 20-40 lobules (TDLUs), in 
which the majority of breast cancers develop. B) Human TDLU stained with hematoxylin and 
eosin (H&E). Star indicates connective tissue stromal component. Scale bar = 400 μm. C) 
Cross-section of human mammary epithelium stained with H&E. White arrow indicates 
luminal epithelial cells; black arrow indicates myoepithelial cells. Star indicates location of 
lumen. Scale bar = 100 μm. Not pictured: basement membrane. 
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Figure 1.2. In vitro culture models for studies of stromal-epithelial interactions in 
breast 
 
A) Schematic of “direct” co-culture model wherein two cell types are grown together in the 
same tissue culture well. B) Schematic of “transwell” co-culture model. Although the two cell 
types are not in direct physical contact, they are separated by a porous physical barrier and 
can still communicate via soluble signaling mediators. C) Schematic of “organoid” culture. 
Epithelial cells are suspended in a three-dimensional matrix and differentiate into multi-
cellular structures that recapitulate in vivo properties of the mammary gland. D) Cross-
sections of mammary epithelial organoids. Organoids begin as small, multi-cellular 
structures without a visible lumen (left). As they mature, organoids increase in size and 
begin to undergo apoptosis-mediated cavitation (lumen formation; middle). Cell proliferation 
will cease once the organoid reaches its mature, final size (right). Additionally, all cells in the 
center of the organoid will apoptose (contained within the black line), leaving only a single 








p53-DEPENDENT STROMAL-EPITHELIAL INTERACTIONS INDUCE MORPHOLOGIC 
CHANGES IN PRE-MALIGNANT BREAST THAT CORRELATE WITH UNIQUE 






Basal-like and luminal breast cancers exhibit subtype-specific transcriptional and 
phenotypic responses to stroma, but little is known about how stromal-epithelial interactions 
evolve during carcinogenesis. The vast majority of basal-like breast cancers (BBCs) also 
harbor loss-of-function mutations in the tumor suppressor gene, TP53 (p53), but the manner 
in which p53 deficiency per se alters stromal-epithelial interactions in BBC remains 
unexplored. To address these knowledge gaps, we leveraged the MCF10 progression 
series of breast cell lines to engineer a longitudinal, tissue-contextualized model of p53-
deficient, pre-malignant breast. An optical coherence tomography-based imaging platform, 
together with gene expression microarray data, identified novel p53-dependent 
morphogenetic responses to stroma that correlated with unique transcriptional changes. 
p53-dependent stromal-epithelial interactions in benign and pre-malignant BBC may hold 










Breast carcinogenesis occurs in a step-wise fashion, with flat epithelial atypia (FEA), 
atypical ductal hyperplasia (ADH), and ductal carcinoma in situ (DCIS) recognized as bona 
fide, non-obligate precursors to invasive and metastatic disease [141, 160]. However, 
decades of work have failed to identify tumor-intrinsic features that robustly predict 
progression to invasive cancer, suggesting a strong role for the tumor microenvironment in 
mediating the benign to malignant transition [134, 138-142, 160]. However, due to: 1) the 
cross-sectional nature of previous epidemiologic studies of stromal tissue; 2) the reliance of 
these studies on samples from patients with concurrent DCIS and invasive breast cancer; 
and 3) the extensive genomic similarities between in situ and invasive microenvironments 
[151, 152, 155, 161], little is known about the evolution of stromal-epithelial interactions 
during carcinogenesis, particularly during early stages of disease. 
Breast cancer subtypes exhibit distinct interactions with their microenvironments, 
with stroma inducing more extensive gene expression changes in basal-like (BBC) relative 
to luminal breast cancers [85]. BBCs also exhibit unique tumor-intrinsic features, including 
nearly universal loss-of-function (nonsense and frameshift) mutations in the tumor 
suppressor gene, TP53 (p53) [19, 43, 162]. As many previous studies of BBC 
microenvironments have utilized a mix of p53-wild-type and -mutant/deficient cell lines [85, 
150], characterizing stromal-epithelial interactions in the context of this important genetic 
defect is crucial for better understanding the biology of this tumor subtype. 
 We hypothesized that epithelial p53 status modifies stromal-epithelial interactions 
during BBC carcinogenesis. To test this hypothesis, we utilized RNA interference to 
engineer p53-deficient MCF10 series cell lines. The MCF10 progression series is an 
isogenic collection of cell lines that recapitulates features of pre-invasive, basal-like breast 
lesions, including benign fibrocystic change (MCF10A), ADH (MCF10AT1), and DCIS 
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(MCF10DCIS.com, herein referred to as MCF10DCIS), in xenograft models. These isogenic 
lines were utilized in three-dimensional (3D) co-culture assays, and evaluated with both 
gene expression microarrays and an innovative quantitative imaging platform. The resulting 
longitudinal, tissue-contextualized models demonstrate that p53-dependent stromal-
epithelial interactions during BBC carcinogenesis evoke differential morphogenetic 




2.3. Materials and methods 
 
2.3.1. Cell lines  
 The isogenic MCF10 progression series of pre-malignant breast cell lines was 
obtained from the Barbara Ann Karmanos Cancer Institute (Detroit, MI). Cells were 
maintained in Dulbecco’s modified Eagle’s medium/F12 nutrient mix (DMEM/F12, Gibco, 
Life Technologies, Carlsbad, CA), supplemented with 5% horse serum (Gibco), 20 ng/mL 
epidermal growth factor (Invitrogen, Life Technologies), 0.5 μg/mL hydrocortisone (Sigma-
Aldrich, St. Louis, MO), 10 μg/mL insulin (Gibco), and 0.1 μg/mL cholera toxin (Millipore 
Sigma, Burlington MA). Similar to previous studies, we also utilized an hTERT-immortalized 
reduction mammoplasty fibroblast (RMF) cell line, a kind gift from Charlotte Kuperwasser, 
PhD (Tufts University Medical Center, Boston, MA), to circumvent the technical challenges 
(e.g., cell senescence) and substantial genomic heterogeneity associated with the use of 
primary human fibroblasts [85, 150]. RMFs were maintained in RPMI1640 medium 
supplemented with 10% FBS prior to use in 3D cultures (see below). All cells were grown in 
a humidified incubator at 37°C and 5% CO2, and were propagated for <6 months (breast 
cells) or <1 month (RMFs) prior to use in experiments.  
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2.3.2. Endogenous TP53 sequencing and generation of p53-deficient MCF10 
cell line series 
The endogenous TP53 coding sequence in parent MCF10A, MCF10AT1, and 
MCF10DCIS lines was sequenced prior to generation of p53-deficient and control lines. 
RNA was reverse-transcribed (RT2 Reverse Transcription Kit, QIAGEN, Valencia, CA), and 
the resulting cDNA was used to PCR-amplify (Phusion Polymerase, New England BioLabs, 
Ipswich, MA) the TP53 coding sequence with primers specific to canonical human TP53 (F: 
5’-ATGGAGGAGCCGCAGTCAGATC-3’; R: 5’-TCAGTCTGAGTCAGGCCCTTCTG-3’; 
Eurofins Genomics, Louisville, KY). Samples were electrophoresed on and excised from a 
0.8% agarose gel (QIAquick Gel Extraction Kit, QIAGEN), and an A-tailing reaction was 
performed on the purified blunt-ended products (Taq DNA polymerase with ThermoPol 
Buffer, New England Biolabs). The resulting DNA was ligated into the pGEM-T Easy TA 
cloning vector and transformed into JM109 competent cells (Promega, Madison, WI) 
according to the manufacturer’s instructions. Following blue-white colony selection, plasmid 
DNA from 4-5 colonies per cell line was purified (QIAprep Plasmid Miniprep Kit, QIAGEN) 
and sequenced by GeneWiz using SP7 and U6 primers. Sequences were analyzed with 
ApE software. 
shRNA plasmids used to construct the p53-deficient MCF10 cell line series were 
generated by Masutomi and colleagues [163] and purchased from Addgene (p53 knock-
down [-sh:p53] lines: pMKO.1-puro-p53 shRNA 2 [Addgene #10672]; GFP knock-down [-
sh:GFP] control lines: pMKO.1-puro-GFP shRNA [Addgene #10675]). Plasmids were 
transfected into the Phoenix-AMPHO packaging cell line (ATCC, Manassas, VA) using 
Lipofectamine LTX (Invitrogen, Carlsbad, CA) according to the manufacturers’ instructions, 
and the virus-containing supernatants were harvested and directly applied to each of the 3 
parent lines in the MCF10 series. Stable cell populations were established by selection in 1 
μg/mL puromycin for 14 days.  
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2.3.3. Calculation of population doubling time 
Cells were plated at a density of 1 x 105 cells per 60-mm dish and were harvested 
and enumerated every 24 hours for 4 days. Log-phase cell growth was with the regression 
equation, ln(At) = ln(A0) + kt, wherein “At” represents the number of cells present at time “t”; 
“A0” represents the initial number of cells; and “k” represents the first-order rate constant of 
cell growth with units of time-1 [150]. For each cell line, k was computed in each of 3 






 2.3.4. 2D culture RNA isolation and quantitative PCR (qRT-PCR) 
 Total RNA was extracted (RNeasy Mini kit, QIAGEN) and reverse-transcribed (RT2 
Reverse Transcription Kit, QIAGEN) according to the manufacturers’ instructions. Gene 
expression was quantitated with exon-spanning TaqMan Gene Expression Assays (Applied 
Biosystems, Foster City, CA) using an ABI 7900HT Fast real-time PCR machine (Invitrogen) 
using the SsoAdvanced Universal Probes Supermix (Bio-Rad, Hercules, CA). Normalization 
to GAPDH was performed using the ΔΔCt method.  
 
2.3.5. 3D culture conditions 
 Cells were suspended in a biologically derived matrix comprised of 50% phenol red-
free Matrigel (#356237; Corning, Corning, NY) and 50% rat-tail collagen I (#354236; 
Corning) diluted to a final concentration of 1 mg/mL as previously described [68, 71, 150, 
164]. Suspended cells were then seeded into tissue culture plates pre-coated with the same 
matrix, and growth medium was dispensed to the apical side of each culture after 30-60 
minutes. Co-cultures were maintained in MCF10 series growth medium (DMEM/F12), as we 
have previously demonstrated that RMF doubling times in this medium are similar to those 
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observed in RPMI1640 [85, 150]. RMF mono-cultures maintained in DMEM/F12 were used 
as normalization controls for gene expression microarray analyses (see below). 
Corresponding mono- and co-cultures were constructed with the same total starting cell 
number (rather than the same starting number of breast cells) to reduce the potential for 
nutrient deprivation in co-cultures (Table 2.1). Cultures were refreshed every 2-3 days and 
were maintained for 14 days, as both MCF10A and MCF10DCIS organoids cease log-phase 
growth by this time point [68]. 
 
2.3.6. Optical coherence tomography (OCT)-based morphology assay  
 Organoid morphology was quantitated using optical coherence tomography (OCT), a 
method of “optical histology” sensitive to changes in signaling mediator activity, toxicant 
exposure, and cell-cell and cell-matrix interactions [68, 69, 71, 150]. We particularly focused 
on organoid “asphericity,” a unitless morphologic metric defined as the ratio of the volume of 
a perfect sphere with the same surface area as a given organoid to the volume of the 
organoid; a value of 1 is indicative of a perfectly spherical structure [68]. This metric has 
been described to reflect cell invasive potential (i.e., local invasion) [68], and the asphericity 
of MCF10 series control organoids increases with progression to malignancy (Figure 2.1A). 
The OCT system used in the present study has been described in detail previously, 
and consists of a titanium-sapphire laser with a central wavelength and bandwidth of 800 
nm and 120 nm, respectively [68]. Spectral images (200 frames per sample) were collected 
using a custom spectrometer with a Dalsa Piranha line scan CCD camera operated at 2-4 
kHz. As described in previous studies, we used custom MATLAB scripts to quantitate 
organoid asphericity [68, 150]. Briefly, individual organoids were manually identified within 
each image stack, and an intensity threshold was selected for each region of interest to 
distinguish the included organoid from the surrounding matrix (background). Computation of 
organoid morphology was then performed in an automated fashion. To avoid selection bias, 
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organoids that 1) did not overlap with adjacent structures; 2) were not in close proximity to 
the edge of an image frame or the apical surface of the culture; and 3) could be adequately 
distinguished from background were analyzed. For each independent experiment, all 
cultures were grown, imaged, and analyzed simultaneously. An average of ~30-45 
organoids across 2-3 independent experiments was analyzed for each culture condition, and 
all 3D organoid renderings shown in this document are representative. Organoids generated 
for OCT imaging were not utilized in microarray experiments (see below) to circumvent the 
possible transient effects of imaging on gene expression. 
 
2.3.7. 3D culture RNA isolation 
Cultures were rinsed with cold PBS and technical replicates (2 cultures for each of 2 
independent experiments) were transferred into a single tube containing 800 μL of Cell 
Recovery Solution (#354253; Corning) on ice. Each well was rinsed with an additional 1.0 
mL of Cell Recovery Solution to ensure complete transfer of the sample. Phenol-chloroform 
RNA extraction was then performed using QIAzol lysis reagent (QIAGEN) according to the 
manufacturer’s instructions, with modifications: following centrifugal separation of the 
organic and aqueous phases, the aqueous phase was mixed with 100% ethanol at a ratio of 
1:1 and applied to a QIAGEN RNeasy column according to the manufacturer’s instructions. 
RNA concentrations were determined using a NanoDrop 2000 Spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA). Samples were further purified with the RNA Clean and 
Concentrator Kit (Zymo Research, Irvine, CA) as needed. 
 
 
2.3.8. Whole genome microarrays 
RNA from 3D cultures was isolated and quantified as described above, and sample 
quality was determined using the Agilent Tape Station (Santa Clara, CA). All samples had 
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RNA integrity numbers of >7. RNA samples were labeled and amplified using the Agilent 
Low Input Two-Color, QuickAmp Labeling kit (#5190-2306) according to the manufacturer’s 
instructions. Cy-5-labeled cDNAs were generated from all experimental samples, and 
reference RNA (Stratagene Universal Human Reference spiked 1:1000 with MCF-7 RNA 
and 1:1000 ME16C RNA to increase expression of breast cancer genes) was labeled with 
Cy-3. All samples were run on Agilent human 4x44K v2 whole genome microarrays 
(#G4845A). For RMF-only samples, RNA from 4 wells (2 wells from each of 2 independent 
experiments) was pooled, concentrated, and applied to 4 microarrays due to low sample 
concentrations.  
 
2.3.9. Microarray data normalization and analysis  
Microarray data were Lowess-normalized and probes with >80% good data (signal 
>10 dpi in both channels) were selected for further analysis. During data pre-processing, we: 
1) eliminated probes without corresponding ENTREZ Gene IDs; 2) collapsed duplicate 
probes corresponding to the same ENTREZ Gene ID by averaging; and 3) imputed missing 
data using the k-nearest neighbors’ imputation with k = 10. Unless otherwise specified, we 
also excluded genes that did not have at least a two-fold deviation from the mean 
expression in at least one sample. For mono-culture analysis, a pre-processed dataset 
consisting only of epithelial mono-culture samples was constructed; RMF mono-cultures 
were excluded from this dataset because they were only utilized for co-culture data 
normalization (see below). Mono-culture gene expression analysis was conducted using 
significance analysis of microarrays (SAM) procedures as indicated in the text.  
For co-culture data, we first used the method of Buess et al. [165] to normalize co-
cultures to the corresponding mono-cultures grown under identical conditions [85, 150]. This 
expression deconvolution approach estimates the percentage of cancer cells and fibroblasts 
in each co-culture, normalizes the resulting data for additive effects in the mixed-
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composition co-culture sample, and calculates a coefficient of interaction (“I”) for each gene 
by determining the ratio of observed to expected co-culture gene expression. We used this 
approach to generate an I-matrix consisting of interaction coefficients for each gene in all 
co-cultures, which can be analyzed in an identical manner to “conventional” (i.e., non-co-
culture-normalized) microarray data. Estimation of the proportion of breast epithelial cells 
revealed that breast epithelial cells comprised >90% of cells in each co-culture (data not 
shown), indicating that RMF contributions to signaling were ostensibly null at sample 
harvest. We confirmed this result by correlating co-culture gene expression data with that of 
the corresponding breast epithelial monoculture (data not shown). Therefore, co-culture 
gene expression data were analyzed in a manner analogous to that of mono-culture data: A 
pre-processed dataset was created containing only gene expression data from co-culture 
samples. The expression of each gene in replicate knock-down co-culture samples was 
normalized to the average expression of that gene across the corresponding control co-
culture samples, and the resulting dataset was median centered and analyzed via SAM as 
indicated in the text. Gene lists were functionally annotated with DAVID Bioinformatics 
Resources, version 6.8 (https://david.ncifcrf.gov).  
 
2.3.10. Statistics 
All statistical analyses were performed with GraphPad Prism version 6.0 (GraphPad 
Inc., La Jolla, CA). Data were analyzed using the two-tailed unpaired student’s t-test or two-
way ANOVA with Tukey’s multiple comparison test as appropriate. Error bars indicate the 









2.4.1. Phenotypic characterization of p53-deficient MCF10 series 
To study the effects of p53 deficiency in pre-malignant BBC cells, a p53-targeting 
shRNA construct (herein referred to as, “-sh:p53”) was stably expressed in MCF10A, 
MCF10AT1, and MCF10DCIS cells; the 3 parent lines were confirmed by our laboratory to 
express wild-type TP53 (data not shown). Stable lines expressing a GFP-targeting shRNA 
construct (“-sh:GFP”) were also generated as negative controls. qRT-PCR analysis 
indicated that a >80% reduction in p53 expression was achieved for each knock-down cell 
line in our panel (Figure 2.1B; p<0.0001 sh:p53 vs. sh:GFP for each isogenic cell line pair). 
Additionally, growth curve analyses of cells grown on plastic revealed that population 
doubling times did not significantly differ between the corresponding -sh:GFP and -sh:p53 
isogenic pairs (e.g., MCF10A-sh:GFP vs. MCF10A-sh:p53; data not shown). Moreover, -
sh:p53, but not –sh:GFP, cells exhibited the ability to survive and grow in the absence of 
serum (data not shown), consistent with expected results. 
  
2.4.2. Contextual responses of pre-malignant BBC cells to p53 deficiency  
We employed 3D morphogenesis assays to track the evolution of epithelial 
morphogenesis with pre-invasive BBC progression and in response to epithelial p53 
deficiency. Epithelial cells grown in a 1:1 mixture of Matrigel and collagen I differentiate into 
3D, multicellular organoids that recapitulate the in vivo structure of mammary gland acini, 
enabling studies of both physiologic and pathologic processes in a tissue-relevant context 
[65, 150]. Organoid morphogenesis, which requires coordination of cell proliferation, 
apoptosis, and migration [166], was quantitated with OCT imaging. To characterize the 
morphogenetic responses of pre-invasive BBC cells to p53 deficiency, OCT-based 
quantitation of asphericity was performed on mono-cultures after 2 weeks of culture (Figure 
 
 36 
2.2A-C). We observed that benign MCF10A organoids exhibited significantly increased 
asphericity in response to p53 expression deficits (p = 0.0023), but that the morphologic 
characteristics of MCF10AT1 and MCF10DCIS organoids were independent of p53 status.  
We next determined whether the morphologic responses (or lack thereof) of each 
cell line to p53-knock-down correlated with unique patterns of gene expression. First, a 2-
class SAM analysis of the top ~10% most variable genes across mono-culture samples (all 
3 -sh:p53 samples vs. all 3 -sh:GFP controls) revealed that p53 deficiency did not elicit a 
common transcriptional response; in fact, gene expression patterns across the 6 cell lines 
were highly variable (data not shown). In light of this result, we next sought to understand 
how transcriptional responses to p53 deficiency varied across cell lines. The expression of 
each gene in replicate -sh:p53 mono-culture samples was normalized to the average 
expression of that gene across the corresponding -sh:GFP control samples, and a multi-
class SAM analysis on the resulting data set identified 47 genes that were significantly 
differentially regulated among the three p53-knock-down cell lines (FDR = 10.02%).  
Previous work in our laboratory has demonstrated that stromal cells induce broad 
transcriptional changes in cancer cells [85, 150]. Therefore, we considered that cell-line 
specific responses to p53 deficiency may also depend upon microenvironmental context. 
Each line in the MCF10 series was co-cultured with fibroblasts (RMFs) at a ratio of 1:1, and 
microarray analyses were performed after 2 weeks. To facilitate comparisons with mono-
cultures, each gene in replicate -sh:p53 co-culture samples was normalized to the average 
expression of that gene across the corresponding -sh:GFP co-culture controls. A multi-class 
SAM on the resulting normalized data set identified 69 genes that were significantly 
differentially regulated among p53-deficient co-cultures (FDR = 9.50%). The 69 genes from 
this list, as well as the 47 genes differentially expressed among p53-knock-down 
monocultures, are presented in a single heat map (Figure 2.3). This expression map shows 
that transcriptional responses to p53 deficiency are contextual, differing both by cell line 
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(stage of disease) and according to the presence or absence of paracrine signals from 
stroma.  
One group of genes in which we were particularly interested was up-regulated in 
MCF10A-sh:p53 mono-cultures relative to the remaining culture conditions (grey bar in 
Figure 2.3). These genes are nearly uniformly down-regulated with progression both in the 
presence and absence of stroma; hence, their dysregulation may have potent effects on 
charting the natural history of a p53-deficient BBC. In particular, we noted that ATF7IP, a 
binding partner of the transcriptional repressor MBD1, was present in this cluster, potentially 
indicating that a more transcriptionally primed or active state is induced with progression 
and in response to fibroblasts.  
A second gene cluster of interest was that for which expression was generally 
highest in MCF10DCIS-sh:p53 co-cultures compared to the remaining culture conditions 
(black bar in Figure 2.3). In the context of p53 deficiency, these genes may promote the 
pre-malignant to invasive BBC transition [151]. Three chaperone or DNA repair genes were 
present in this cluster (DNAJ4B, C1GALT1C1, and IPPK), suggesting that a general stress 
response may be induced in p53-deficient MCF10DCIS co-cultures. Up-regulation of IPPK 
may also confer a survival advantage in these cells [167]. In addition, two genes in this 
cluster, including MMP23 and DOCK1, have been previously implicated as poor prognostic 
markers in different cancers: MMP23 expression in melanoma is associated with deficits in 
anti-tumor immune function and poor responses to immunotherapies [168], whereas high 
DOCK1 expression correlates with poor survival in BBC and mediates HER2+ breast cancer 
metastatic progression [169]. Finally, we identified the pseudogene CRYBB2PS1 
immediately outside this cluster. This pseudogene is homologous to the protein-coding gene 
CRYBB2, the latter of which is linked to race-associated disparities in breast cancer 
outcomes [170-172]. This gene was strongly down-regulated in MCF10A-sh:p53 cells 
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relative to nearly all other culture conditions, but was less robustly upregulated in 
MCF10DCIS-sh:p53 cells in response to stroma.  
 
2.4.3. p53 deficiency accelerates morphologic responses of pre-invasive BBC 
cells to fibroblast co-culture 
 Having established that the genomic responses of benign breast cells to p53 
deficiency change according to the presence of microenvironmental signals, we next 
explored whether stromal context also elicits phenotypic changes in cells. OCT-based 
asphericity analyses were performed on co-cultures after 2 weeks of culture. Asphericity of 
acini in co-culture was compared to that of organoids in the corresponding epithelial mono-
culture. Organoid asphericity in response to co-culture is presented in Figure 2.4. The 
morphologies of both p53-deficient and -sufficient MCF10DCIS organoids were independent 
of stroma-derived signals (Figure 2.4, right), but fibroblasts did exert morphologic effects on 
acini at earlier stages of pre-malignancy. Among the control cell lines, fibroblasts 
significantly increased the asphericity of MCF10AT1-sh:GFP organoids (p = 0.0144 vs. 
MCF10AT1-sh:GFP mono-culture; Figure 2.4, center). In p53 deficient cells, in contrast, 
fibroblast-induced increases in organoid asphericity were observed in both MCF10A-sh:p53 
(p = 0.0070 vs. MCF10A-sh:p53 mono-culture; Figure 2.4, left) and MCF10AT1-sh:p53 
(p<0.0001 vs. MCF10AT1-sh:p53 mono-culture; Figure 2.4, center) cultures. These data 
indicate that stromal fibroblasts alter the morphologic features of both p53-sufficient and -
deficient breast epithelial cells at early stages of pre-malignancy, but that morphogenetic 
changes are accelerated in the setting of p53 deficiency.  
 
 2.4.4. p53-dependent stromal-epithelial interactions are cell line-specific  
 Given that the timing of morphologic responses to co-culture was dependent upon 
epithelial p53 status, we sought to further characterize p53-dependent stromal-epithelial 
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interactions across the three cell lines. Each gene in replicate -sh:p53 mono-culture samples 
was normalized to the average expression of that gene across the corresponding mono-
culture controls, and each gene in replicate -sh:p53 co-culture samples was normalized to 
the average expression of that gene across the corresponding co-culture controls. A 2-class 
SAM on the resulting normalized dataset (normalized knock-down mono-cultures vs. 
normalized knock-down co-cultures) identified only 7 genes that were significantly changed 
in p53-deficient cells in response to co-culture; these genes represent a common response 
to stroma shared by all p53-deficient cell lines (FDR = 12.2%; data not shown). Using the 
same method, we performed this analysis for each isogenic cell line pair in isolation and 
visualized the 3 resulting lists of significant genes with a single heat map (Figure 2.5). This 
heat map represents the unique p53-dependent responses of each cell line to co-culture. 
The broadest range of expression differences was observed in co-cultured vs. mono-
cultured MCF10DCIS-sh:p53 organoids. Notably, 21 genes associated with phosphoprotein 
signaling were upregulated in MCF10DCIS-sh:p53 co-cultures (Table 2.2; black bar in 
Figure 2.5 shows all genes upregulated in co-cultured MCF10DCIS-sh:p53 cells), 
suggesting activation of a diverse array of pathways in response to stroma. Additionally, 
consistent with previous reports demonstrating that fibroblasts promote the in situ to 
invasive breast cancer transition [155], three genes associated with metalloproteinase 
activity (MMP23B, YME1L1, TMEM27) were upregulated in MCF10DCIS-sh:p53 co-cultures 
compared to mono-cultures. Furthermore, in agreement with our previous finding that 
stroma up-regulates inflammatory and immune response genes in invasive BBCs [85], we 
noted that the pro-inflammatory interleukin receptor IL12RB1 was also induced in 
MCF10DCIS-sh:p53 co-cultures. Down-regulated genes in p53-deficient MCF10DCIS co-
cultures (grey bar in Figure 2.5) included those associated with cell proliferation, 
differentiation, and apoptosis (POLI, MRPS30, ETS2, ETV4, NKAP, GDF7, MAP2K7, and 
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MEGF8). Taken together, these results imply that p53 deficiency in DCIS may accelerate 





 Mutations in epithelial cells undoubtedly play indispensible roles in breast 
carcinogenesis, but the importance of stroma in tumor development is increasingly 
recognized. Dramatic gene expression changes occur in numerous stromal cell populations 
during progression to malignant disease [151], and pre-invasive breast stroma exhibits 
extensive genomic overlap with the microenvironment of malignant carcinomas [161, 173]. 
However, carcinogenesis is an evolutionary process that requires complementary input from 
both epithelium and stroma [85, 150], and it is important to understand how specific 
communication patterns change throughout the course of tumor development, particularly in 
the context of breast cancer subtypes. We previously used co-culture models to 
demonstrate that coordinated signaling responses occur in both stromal and epithelial cells 
during malignant BBC progression [150]. Herein, we build upon this work by elucidating how 
tissue-contextualized stromal-epithelial interactions are altered in the context of a genetic 
defect (p53 loss) with clinical relevance to this tumor subtype. 
 Three-dimensional organoid morphogenesis requires a coordinated balance of cell 
proliferation, apoptosis, and migration [166]. Previous 3D culture-based studies have relied 
upon integration of multiple histologic assays (e.g., BrdU, TUNEL, and immunohistochemical 
staining) to characterize these processes [64, 174, 175]. However, a general limitation to 
this approach is that histology is subject to selection bias, and multiple sections or 
microscopic fields must be analyzed per sample to confidently assess changes in phenotype 
or protein expression. In contrast, our OCT-based asphericity assay was able to capture the 
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net result of multiple cellular processes across individual organoids in a single metric. 
Organoid volume was also measured in this study as a more direct proxy of cell proliferation 
(data not shown), and changes in volume tracked closely with trends in asphericity. 
Moreover, we have previously used OCT to quantitate the intracellular dynamics of organoid 
cultures in response to toxicants, exogenous signaling mediators, and tissue culture 
composition [68, 69, 71, 150]; hence, in the present study, we probed novel, contextual cell-
cell interactions with a well-validated system. In our mono-culture experiments, benign 
breast epithelium (MCF10A) was the only cell type to exhibit morphologic responses to p53 
deficiency; in contrast, the increasingly aspherical morphologies of MCF10AT1 and 
MCF10DCIS organoids were independent of p53 status. Nevertheless, the transcriptional 
responses to p53 loss did vary among all 3 cell types, suggesting that the specific point at 
which p53 is mutated/lost in human BBCs has potential to influence the natural history of a 
given tumor.  
More diverse changes in organoid asphericity were seen in co-culture, which further 
depended upon epithelial p53 status. Fibroblast-induced morphologic changes initially 
observed in p53-sufficient ADH acini (MCF10AT1-sh:GFP) were accelerated in the context 
of p53 deficiency, first manifesting at the benign stage (MCF10A-sh:p53). Although prior 
research in this area has not considered the p53 status of epithelial cells, our results differ 
from those in previous reports. Sadlonova et al. demonstrated that normal breast-associated 
fibroblasts, but not cancer-associated breast fibroblasts, inhibited the proliferation of 
MCF10AT1 organoids [174, 175]. However, the discrepancies between these studies and 
the present report may reflect methodologic differences, highlighting that co-culture 
conditions such as cell ratios; matrix composition and culture construction (cells grown on 
top of a matrix layer vs. embedded within); and the character and source of fibroblasts 




Compared to a previous study of fibroblast-MCF10 series interactions [150], the 
present study identified far fewer transcriptional changes in epithelial cells in response to 
stroma. The relatively limited gene expression changes identified herein may have arisen 
due to the generally inhibitory effect of basement membrane proteins on cell signaling in 3D 
cultures [176, 177]. Alternatively, methodologic consequences may be considered. Herein, 
cells were embedded within a semi-solid matrix that almost certainly limited the diffusion 
range of soluble factors. In ref. [150], however, stromal and epithelial cells were cultured 
together on plastic (in the same culture well), enabling both physical cell-cell contacts and 
reduced dependence on the stability of signaling mediators. Finally, RMFs had low 
prevalence (<10% of total cell content) in each 3D culture studied here. This result was 
surprising, because, at least in two-dimensional cultures, fibroblasts and MCF10 series cells 
exhibit similar population doubling times. Therefore, the most dramatic stroma-induced gene 
expression changes in our model likely occur during the first few days of culture when the 
proportions of each cell type are roughly equivalent. Transcriptional patterns at later time 
points, such as those analyzed here, reflect long-term, steady-state responses to co-culture 
and/or morphologic changes induced therein.  
The aim of this study was to explore how p53-dependent stromal-epithelial 
communication patterns in breast tissue models evolve during progression from pre-
malignant to invasive disease. Some of the identified genes have been previously studied in 
invasive breast cancer, whereas others have only been reported in other tumor types. While 
certain stroma-modified genes may be targets for BBC prevention, the factors identified 
herein must be studied mechanistically in greater detail to evaluate their translational 
relevance. Nevertheless, our results indicate that 3D culture models of pre-invasive breast 
can recapitulate previously described aspects of invasive breast cancer biology, consistent 
with reports that in situ and invasive breast cancers share certain genomic characteristics 
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[143-148]. Simultaneously, these models can also generate new insight into how stroma 




Figure 2.1. Development of a methodology to study p53-dependent stromal-epithelial 




A) Top: Optical coherence tomography (OCT)-based analyses of organoid asphericity. ***p< 
0.001. Bottom: Representative organoid renderings showing increased asphericity with 
progression. B) qRT-PCR analysis of TP53 expression in p53-deficient (-sh:p53) and control 
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Figure 2.2. p53 deficiency increases the asphericity of benign MCF10A organoids 
 
 
A) Top: OCT-based asphericity measurements of MCF10 series organoids in monoculture. -
sh:p53 organoids were compared to their respective -sh:GFP controls. **p<0.01. n = 3 
independent experiments. Error bars indicate mean + SEM. Bottom: Representative 
MCF10A organoid renderings. B) Photomicrographs of MCF10A-sh:GFP and MCF10A-
sh:p53 organoids. Note how some MCF10A organoids have small projections invading the 













































This heat map demonstrates that transcriptional responses to p53 deficiency vary among 
the MCF10 cell lines, both in mono-culture and co-culture. For mono-cultures (blue bar), the 
expression of each gene in replicate -sh:p53 samples was normalized to the average 
expression of that gene across the corresponding -sh:GFP control samples, and data were 
analyzed by multi-class SAM. Co-culture data (gold bar) was analyzed in a similar manner, 













































































































clusters marked by bars are described in detail in the text. The grey bar indicates genes that 
were up-regulated in MCF10A-sh:p53 mono-cultures relative to the remaining culture 
conditions. The black bar indicates genes for which expression was generally highest in 
MCF10DCIS-sh:p53 co-cultures relative to the remaining culture conditions. Fold change 
(log[2R/G]) is relative to median expression. 
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OCT-based asphericity measurements of MCF10 series organoids. For each cell line, co-
cultures were compared to their mono-culture controls. *p<0.05; **p<0.01; ****p<0.0001. n = 
2 independent experiments. Error bars indicate mean + SEM. 
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Figure 2.5. p53-dependent stromal-epithelial interactions are cell line-specific  
 
This gene expression heat map depicts the unique p53-dependent responses of each cell 
line to co-culture. For each cell line, each gene in replicate -sh:p53 mono-culture samples 
was normalized to the average expression of that gene across the corresponding mono-
culture controls, and each gene in replicate -sh:p53 co-culture samples was normalized to 
the average expression of that gene across the corresponding co-culture controls. A 2-class 
SAM on each resulting normalized dataset (normalized knock-down mono-culture vs. 














































































































deficient cells in response to co-culture. All 3 lists were visualized with a single heat map. 
Each cell line is indicated with a different color: blue, gold, and magenta bars depict 
MCF10A-sh:p53, MCF10AT1-sh:p53, and MCF10DCIS-sh:p53 cultures, respectively. Gene 
clusters marked by black and grey bars are discussed in the text; these clusters contain 
genes that were up- and down-regulated, respectively, in MCF10DCIS-sh:p53 cultures in 


















































Breast cells RMFs 
MCF10A DMEM/F12 30,000/mL 15,000/mL 15,000/mL 
MCF10AT1 DMEM/F12 30,000/mL 15,000/mL 15,000/mL 
MCF10DCIS DMEM/F12 30,000/mL 15,000/mL 15,000/mL 













































Table 2.2. Phosphoprotein-associated genes induced by co-culture in MCF10DCIS-
sh:p53 organoids 
 
ENTREZ Gene ID Gene name symbol) 
25966 C2 calcium dependent domain containing 2(C2CD2)   
56474 CTP synthase 2(CTPS2)      
84444 DOT1 like histone lysine methyltransferase(DOT1L)    
11080 DnaJ heat shock protein family (Hsp40) member B4(DNAJB4) 
2733 GLE1, RNA export mediator(GLE1)     
9778 KIAA0232(KIAA0232)        
56950 SET and MYND domain containing 2(SMYD2)   
23480 Sec61 translocon gamma subunit(SEC61G)     
10629 TATA-box binding protein associated factor 6 like(TAF6L)  
4904 Y-box binding protein 1(YBX1)     
8091 high mobility group AT-hook 2(HMGA2)    
10525 hypoxia up-regulated 1(HYOU1)      
3710 inositol 1,4,5-trisphosphate receptor type 3(ITPR3)    
64768 inositol-pentakisphosphate 2-kinase(IPPK)       
55154 
misato 1, mitochondrial distribution and morphology 
regulator(MSTO1)  
8079 myeloid leukemia factor 2(MLF2)     
399687 myosin XVIIIA(MYO18A)       
79834 pseudopodium enriched atypical kinase 1(PEAK1)    
80346 receptor accessory protein 4(REEP4)     
57393 transmembrane protein 27(TMEM27)      

















Claudin-low breast cancer (CLBC) is an invasive triple-negative subtype 
characterized by the presence of a growth-permissive, inflammatory microenvironment, to 
which myeloid-lineage macrophages are a major contributor. Macrophage Glut1 (Slc2a1)-
mediated glucose metabolism is a critical regulator of the inflammatory responsiveness of 
this cell type; thus, the goal of this study was to evaluate the effect of myeloid lineage Glut1 
loss on CLBC progression. Myeloid-specific Glut1 knockout (Glut1M-/-) mice and littermate 
controls (Glut1MFl/Fl) were orthotopically injected with syngeneic M-Wnt cells, a model of 
CLBC that recapitulates genomic and molecular features of human disease. We show 
herein that mammary tissue macrophages (MTMs) of Glut1M-/- compared to Glut1MFl/Fl 
animals were skewed toward an anti-inflammatory phenotype, and that M-Wnt tumor 
progression was impeded in Glut1M-/- animals. Collectively, our results indicate that myeloid 
Glut1 regulates the inflammatory microenvironment of both normal mammary and breast 









Claudin-low breast cancers (CLBCs) are invasive triple-negative tumors 
characterized in part by steady-state up-regulation of immune response genes and the 
presence of histologically conspicuous leukocytic infiltrates [12, 49, 51]. In particular, 
myeloid-lineage tumor-associated macrophages (TAMs) are highly prevalent in triple-
negative breast cancers (TNBCs), and possess a diverse array of recognized roles in 
promoting inflammation in the tumor microenvironment [98, 100, 101, 103, 104, 178, 179]. 
Given the growth-permissive, mutagenic nature of chronic inflammation [100, 180], 
processes or interactions that reduce macrophage inflammatory responsiveness may 
represent promising targets for novel CLBC therapies.  
Energy metabolism is an important component of macrophage inflammatory 
responsiveness. Pro-inflammatory macrophages preferentially metabolize glucose as an 
energy substrate [181] in a mechanism reliant upon the glucose transporter, Glut1 (encoded 
by Slc2a1) [182, 183 [submitted manuscript]]. Indeed, Glut1 overexpression was sufficient to 
confer a pro-inflammatory phenotype in ex vivo bone marrow-derived macrophages 
(BMDMs) even in the absence of exogenous pro-inflammatory stimuli, suggesting that 
macrophage metabolic and inflammatory states are tightly linked [182]. Similarly, BMDMs 
from myeloid-specific Glut1 knockout mice demonstrated reduced expression of pro-
inflammatory and oxidative stress markers, as well as an enhanced capacity to buffer 
against oxidative stressors [183]. Taken together, these results suggest that modulation of 
macrophage metabolism is a powerful means by which to alter the inflammatory 
responsiveness of this cell type, with potential to prevent or delay inflammation-associated 
mechanisms linked to breast cancer. 
In this paper, we explored the consequences of myeloid Glut1 deficiency on CLBC 
progression, with a particular emphasis on macrophage-associated features of the tumor 
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microenvironment. Myeloid-specific Glut1 knockout mice (LysM-Cre; Slc2a1Fl/Fl [“Glut1M-/-”]) 
and floxed littermate controls (“Glut1MFl/Fl”) [183] were orthotopically injected with M-Wnt 
cells, a model of CLBC that recapitulates key genomic and histologic features of human 
disease [184]. Our results underscore a need to comprehensively evaluate the role of the 
tumor immune microenvironment in CLBC progression, and to further define potentially 
unique macrophage phenotypes in normal mammary and breast cancer. 
 
 
3.3. Materials and methods 
 
3.3.1. Animal model 
All animal studies were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill and were performed in 
accordance with the recommendations of the Panel on Euthanasia of the American 
Veterinary Medical Association. Animal facilities at UNC are accredited by the Association 
for Assessment and Accreditation of Laboratory Animal Care (AAALAC), and veterinary care 
meets National Institutes of Health standards set forth in the Guide for the Care and Use of 
Laboratory Animals (DHHS Publication No. (NIH) 85-23 Revised 1985). UNC also accepts 
as mandatory the Public Health Service Policy on Humane Care and Use of Laboratory 
Animals by Awardee Institutions, as well as NIH Principles for the Utilization and Care of 
Vertebrate Animals Used in Testing, Research, and Training. Mice were housed in a 
climate-controlled facility with a 12-hour light-dark cycle, and were given ad libitum access to 
water and diet. Glut1M-/- and Glut1MFl/Fl on the C57BL/6J background have been described 
previously [183]. Glut1Fl/Fl mice used for breeding were a kind gift from Dr. E. Dale Abel. At 
three weeks of age, female mice were weaned onto a purified diet delivering 10% kcal from 
fat (#D12450J). Animals were weighed weekly from 3 weeks of age until euthanasia (see 
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below) to monitor the impact of experimental procedures on overall health. Expected trends 
in mouse growth rates were observed, and body weights did not significantly differ by 
genotype at any time point (data not shown). 
  
3.3.2. Flow cytometric analysis of mammary tissue macrophages (MTMs)  
Female mice were euthanized via CO2 asphyxiation and cervical dislocation at 18 
weeks of age (n = 3 per genotype group). The left and right abdominal (4th and 7th) MFPs 
were removed and the intramammary lymph nodes excised. Fat pads were transferred to ice 
cold high-glucose Dulbecco’s Modified Eagle Medium (DMEM, Corning, Corning, NY) 
containing 20 mM HEPES buffer (Cellgro, Manassas, VA), and were minced with surgical 
scissors. Both MFPs from each mouse were then digested in 2 mg/mL Type I collagenase 
(Worthington, Lakewood, NJ) on a rotating incubator for 45-60 min. A single-cell suspension 
was generated via mechanical dissociation with a Stomacher® 80 Biomaster small tissue 
lab paddle blender (Seward, Worthing, West Sussex, United Kingdom). Suspensions were 
diluted with an equal volume of HEPES-buffered DMEM and filtered through a 100-µm cell 
strainer, followed by centrifugation at 200 x g for 10 min at 4°C to generate an immune cell-
enriched stromal-vascular fraction (SVF). The resulting SVF pellet was resuspended in 
HEPES-buffered DMEM and digested with DNase I (Sigma, St. Louis, MO). Red blood cells 
incubated in ACK lysis buffer (Gibco, Gaithersburg, MD) for 3-5 min at RT. The resulting 
SVF cells from each mouse were transferred to separate low-adhesion microcentrifuge 
tubes, blocked with Fc Block (CD16/32) (Biolegend, San Diego, CA), and stained with pre-
titrated antibodies (Table 3.1 for antibody information and dilutions). MTMs were defined as 
CD45+CD11b+CD64+, as CD64 has been reported as a reliable marker to distinguish 
adipose tissue macrophages from CD64- myeloid lineage dendritic cells [185, 186]. Viability 
staining was conducted using Zombie GreenTM fixable viability dye (Biolegend) in DPBS as 
directed. Extracellular antigen staining was conducted using antibodies diluted in DPBS 
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containing 1% FBS and 5 mM EDTA. Cells were then washed and fixed/permeabilized using 
Cytofix/Cytoperm™ Fixation/Permeabilization solution (BD Biosciences, San Jose, CA), and 
incubated with antibodies to intracellular antigens (Table 3.1) diluted in BD Perm/Wash™ 
Buffer overnight at 4°C with gentle agitation. SVF cells were then washed twice with 1X 
Perm/Wash™ solution, re-suspended in DPBS, and filtered through a 30-µm filter. SVF cells 
were analyzed on a BD™ LSR II flow cytometer. Compensation was set using single-stained 
cellular controls and gating was determined based on fluorescence-minus-one (FMO) 
controls. Data were analyzed with FlowJo (FlowJo, LLC, Ashland, OR). 
 
3.3.3. Orthotopic tumor model and tissue collection 
At 13 weeks of age, female mice (n = 15-20 per group) received an ipsilateral 
orthotopic injection of 5x104 viable M-Wnt tumor cells (derived from syngeneic C57BL/6J 
mice) into the 4th mammary gland as previously described [184] (Figure 3.1). Mice were 
palpated three times weekly to monitor tumor growth. Tumors were measured with 
electronic calipers and ellipsoid tumor volume was calculated as in ref. [187]. Mice were 
euthanized via CO2 asphyxiation and cervical dislocation at tumor maximum size (1 cm. in 
the largest dimension). Tumors and contralateral (un-injected) 9th mammary glands were 
collected at sacrifice, and samples were divided in half for both snap freezing and formalin 
fixation. Contralateral mammary glands from 18-week-old tumor-bearing mice (euthanized 
5.0 weeks after M-Wnt cell injection) were used in further molecular analyses to facilitate 
direct comparisons with flow cytometric profiling of MTMs (see above). Molecular tumor 
analyses were conducted on size-matched specimens measuring 1.0 + 0.25 cm in the 






3.3.4. Quantitative RT-PCR (qRT-PCR) 
 Snap-frozen tumor specimens and un-injected contralateral mammary glands from 
tumor-bearing mice were pulverized under liquid nitrogen. Total RNA was extracted 
(RNeasy Mini Plus kit, QIAGEN, Valencia, CA) and reverse-transcribed (500 ng per sample; 
iScript Reverse Transcription Supermix, Bio-Rad) according to the manufacturers’ 
instructions. Gene expression was quantitated using TaqMan Gene Expression Assays 
(Applied Biosystems, Foster City, CA), except for Il10, Ccl2, and Nos2 which were 
measured using Roche Universal Probe Library Assays (Roche Diagnostics US, 
Indianapolis, IN) with the following oligonucleotide pairs: Il10: F: 5’-
CAGAGCCACATGCTCCTAGA-3’; R: 5’-GTCCAGCTGGTCCTTTGTTT-3’; Ccl2: F: 5’-
AGCACCAGCCAACTCTCACT-3’; R: 5’-GTGGGGCGTTAACTGCAT-3’; and Nos2: F: 5’-
TGACACACAGCGCTACAACA-3’; R: 5’-GCCAGTGTGTGGGTCTCC-3’. All samples were 
run on an ABI 7900HT Fast real-time PCR machine (Invitrogen, Carlsbad, CA) using the 
SsoAdvanced Universal Probes Supermix (Bio-Rad). Genes of interest were normalized to 
18S rRNA using the ΔΔCt method.  
  
3.3.5. Digital histology  
Staining: Formalin-fixed, paraffin-embedded (FFPE) tumor and contralateral 
mammary tissue specimens were sectioned at 5 μm and mounted on positively charged 
glass slides. Immunohistochemical (IHC) staining was conducted using pre-titrated 
antibodies (Table 3.2) according to previously described procedures [188], and no-primary 
controls were employed for each stain. Hematoxylin and eosin staining was also performed 
on FFPE tumor sections according to standard protocols. 
Tissue annotation: Stained slides were scanned into digital images using the Aperio 
ScanScope CS system (Aperio Technologies, Vista, CA). Aberrations in the tissue, as well 
as areas of non-mammary or non-tumor tissue (e.g., skin, lymph nodes, muscle) were 
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excluded from digital analyses. All annotations were made by an investigator blinded to 
mouse genotype.  
Quantitative histology: Diaminobenzidine (DAB) staining in IHC-stained slides was 
analyzed quantitatively using Aperio ImageScope algorithms (“IHC Nuclear” algorithm for 
Ki67 staining; “Color Deconvolution” algorithm for remaining IHC markers except for cleaved 
caspase-3) [188]. Cleaved caspase-3 expression was quantitated using the “positive pixel 
count” algorithm; only cells with “strong positive” staining, which exhibited a rounded-up 
apoptotic morphology, were analyzed. Positive DAB staining in negative control (no primary 
antibody) slides was subtracted from the corresponding stained samples as non-specific 
background. For all analyses, tissue sections were examined in their entirety. All images 
shown herein are representative of a given tissue section and genotype group. 
 
3.3.6. Luminex assays 
 Tumor cytokines and chemokines were measured using the Bio-Plex Multiplex 
Immunoassay System with Luminex xMAP Technology (Bio-Rad, Hercules, CA) according 
to the manufacturer’s instructions. Tumors were pulverized under liquid nitrogen and 100 mg 
of each sample was diluted in 500 μL of RIPA buffer containing 1x Halt Protease Inhibitor 
Cocktail (Thermo Scientific, Waltham, MA). Samples were homogenized and centrifuged at 
16000 x g for 20 minutes at 4°C, and a bicinchoninic acid (BCA) assay (Pierce, Waltham, 
MA) was performed on sample supernatants. Supernatants were then diluted to 450 μg/mL, 




Statistical analyses were performed using GraphPad Prism version 7.0 (GraphPad 
Inc., La Jolla, CA). For flow cytometric analyses of marker distribution between Glut1M-/- and 
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Glut1MFl/Fl mice, statistical significance was determined with multiple t-tests (1 per row [cell 
subpopulation/quadrant]) correcting for multiple comparisons using the Holm-Sidak method 
with alpha = 0.05. As each cell subpopulation originated from the same sample, 
computations assumed that all rows were sampled from a population with the same 
standard deviation. All other data were analyzed using the two-tailed unpaired student’s t-
test or log-rank test as appropriate. Unless otherwise specified, error bars represent the 
mean + standard error of the mean (SEM), and statistical outliers were identified using the 
robust non-linear regression with outlier removal (ROUT) method with Q = 1%. For all 





3.4.1. Myeloid Glut1 loss reduced MTM inducible nitric oxide synthase (iNOS) 
expression  
As a first step to elucidating the effect of myeloid Glut1 loss on CLBC progression, 
we used flow cytometry to characterize the immune microenvironment of the normal 
mammary gland, with a particular emphasis on mammary tissue macrophages (MTMs). 
Macrophages are the most highly represented immune cell type in the mouse and human 
mammary gland, and are crucial regulators of initiation, invasion, and metastasis in breast 
cancer [25]. To determine whether myeloid-specific Glut1 knockout altered mammary 
immune cell proportions, we quantitated total leukocyte (CD45+), myeloid cell 
(CD45+CD11b+), and MTM (CD45+CD11b+CD64+) content in freshly isolated MFP 
specimens of 18-week-old mice (see gating strategy in Figure 3.2). The proportions of each 
cell type did not vary by genotype (data not shown). 
 
 61 
We next sought to characterize specific immunophenotypes of MTMs in Glut1M-/- and 
Glut1MFl/Fl mice. Based on recent work in mice and humans suggesting that macrophages in 
adipose-rich tissues exhibit “mixed” expression of pro- and anti-inflammatory markers [189-
195], we quantitated the expression of iNOS and arginase 1 (ARG1), canonical pro- and 
anti-inflammatory markers, respectively, among macrophages in the mammary fat pad. 
There were no significant Glut1-driven differences in the proportions of classically defined 
M1 (ARG1-iNOS+) or M2 (ARG1+iNOS-) macrophages (Figure 3.3A). Interestingly, however, 
the proportion of ARG1+iNOS+ MTMs was diminished in Glut1M-/- relative to Glut1MFl/Fl mice 
(Figure 3.3A; p = 0.0086 Glut1M-/- vs. Glut1MFl/Fl LFD). In sum, the percentage of iNOS+ 
MTMs (irrespective of ARG1 positivity) was reduced in the absence of myeloid Glut1.  
To determine whether select MTM subpopulation(s) were driving observed 
differences in ARG1/iNOS distribution, we stratified MTMs based on MHCII expression level 
(hi vs. lo/-). A significantly increased proportion of MHCIIhi MTMs was detected in MFP of 
Glut1M-/- vs. Glut1MFl/Fl mice (p = 0.0034) (Figure 3.3B), but no significant Glut1-mediated 
differences in ARG1 or iNOS expression in MHCIIhi MTMs were observed by analysis of 
median fluorescence intensities (MFIs) (data not shown). In contrast, the proportion of 
MTMs negative for or expressing low levels of MHCII (MHCIIlo/-) did not significantly differ 
between Glut1M-/- and Glut1MFl/Fl mice (Figure 3.3B). Interestingly, however, in this MHCIIlo/- 
population, the proportion of ARG1+iNOS+ MTMs was significantly reduced in Glut1M-/- 
compared to Glut1MFl/Fl mice (p = 0.0216; Figure 3.3C). This finding suggests that the 
observed reductions in ARG1+iNOS+ cells among total MTMs (Figure 3.3A) was driven by 
differential expression of ARG1 and/or iNOS within the MHCIIlo/- subpopulation.  
To gain insight into the cellular and molecular basis for the observed Glut1-driven 
shifts in ARG1/iNOS expression distribution among MHCIIlo/- MTMs, we next analyzed 
expression of ARG1 and iNOS within this subpopulation. Quantification of ARG1 and iNOS 
MFIs in MHCIIlo/- MTMs revealed reduced iNOS expression, with no significant change in 
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ARG1 expression (Figure 3.3D p = 0.0229 Glut1M-/- vs. Glut1MFl/Fl). In sum, compared to 
those in Glut1MFl/Fl MFP, MTMs of Glut1M-/- mice exhibited diminished pro-inflammatory iNOS 
expression, with the MHCIIlo/- subpopulation predominately driving this reduction.  
 
3.4.2. Myeloid-specific Glut1 knockout did not alter markers of mammary gland 
inflammation  
As MTMs in Glut1M-/- mice exhibited diminished pro-inflammatory iNOS expression, 
we reasoned that Glut1M-/- MFP would also display attenuated inflammatory mediator 
expression. To facilitate temporal comparisons with flow cytometry data, we quantitated the 
expression of cytokines and chemokines with recognized roles in breast cancer onset and 
progression [25] in MFP tissue from 18-week-old mice. None of the factors in our panel (Il6, 
Il10, Il12, Tnf, Ccl2, Il1b) were differentially regulated between Glut1M-/- and Glut1MFl/Fl MFP 
(data not shown), perhaps reflecting the status of macrophages as minority components of 
the normal mammary gland.   
 
3.4.3. Myeloid-specific Glut1 knockout delayed CLBC growth  
 Having profiled select inflammatory characteristics of the mammary gland with 
particular relevance to breast cancer, we next examined the impact of myeloid-specific Glut1 
deficiency on CLBC progression. Glut1M-/- mice and Glut1MFl/Fl controls were orthotopically 
injected with M-Wnt CLBC cells at 13 weeks of age. Similar to previous reports [184], M-Wnt 
tumors in our study were poorly differentiated, contained abundant intratumoral adipocytes 
(Figure 3.4A), and exhibited microvascular proliferation (CD31 positivity) (Figure 3.4B). 
Quantitation of CD31 staining indicated that tumor angiogenesis did not dramatically vary by 
genotype (Figure 3.4B), and in both groups, blood vessels were most prevalent proximal to 
the tumor margins.  
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Tumor progression was tracked to a pre-determined maximum size (1 cm. in the 
largest dimension). Tumors in Glut1M-/- mice were substantially smaller than those in 
Glut1MFl/Fl controls after 5.5 weeks of growth (p = 0.0593; Figure 3.5A). We also noticed that 
Glut1M-/- tumors appeared to grow for a longer period of time before reaching the 1-cm cutoff, 
which was confirmed by Kaplan-Meier analysis (Figure 3.5B; p = 0.0137 Glut1M-/- vs. 
Glut1MFl/Fl). This differential tumor progression could not be attributed to significant 
differences in time to palpation of detectable lesions (data not shown), or tumor cell 
proliferation (Ki67 staining; Figure 3.4C) or apoptosis (cleaved caspase-3 staining; Figure 
3.4D). 
 
3.4.4. Glut1M-/- immune microenvironments may suppress tumor growth  
Heterotypic cancer-stroma interactions, together with tissue remodeling induced by 
tumor immune infiltrates, foster a growth-permissive microenvironment characterized in part 
by chronic, low-grade inflammation [100, 188, 196]. Given the known role of Glut1 in the 
regulation of macrophage inflammatory character [182, 183], as well as the high prevalence 
of TAMs in TNBCs [103, 178], we reasoned that delayed tumor growth in Glut1M-/- mice 
would correlate with reduced expression of inflammatory cytokines and chemokines in the 
tumor microenvironment. Consistent with our hypothesis, we observed striking reductions in 
the protein concentrations of MCP-1 (CCL2), IL-12β, TNFα, and IL-10 in Glut1M-/- relative to 
Glut1MFl/Fl tumors (Figures 3.6A-D; p = 0.0064, p = 0.0171, p = 0.0050, and p = 0.0003, 
respectively), even in the absence of significant genotype-driven differences in TAM content 
(Figure 3.6E). This result suggests that the inflammatory potential of TAMs, like MTMs, may 
be reduced in Glut1M-/- mice. As the inflammatory properties of macrophages are intimately 
linked to cell behavior [105], we began to explore whether loss of myeloid Glut1 elicited 
alterations in macrophage function. Antigen presentation to T cells is an important general 
function of macrophages, particularly in the context of T cell-mediated anti-tumor immunity. 
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Hence, we quantitated the expression of select antigen presenting cell (APC) markers [197] 
in CLBC tumors. While Cd74 did not significantly differ by genotype, we observed a 
significant up-regulation of Cd80 (p = 0.0026) and Cd86 (p = 0.0073) in Glut1M-/- compared 
to Glut1MFl/Fl tumors (Figures 3.6F-G). Taken together, these data indicate that Glut1M-/- 
CLBCs are characterized by unique inflammatory microenvironments with potential to 





Specific roles of the tumor microenvironment in promoting breast cancer progression 
are increasingly understood. However, as the most recently recognized breast cancer 
subtype [48], tumor-microenvironment interactions in CLBC are poorly defined. Steady-state 
up-regulation of inflammatory and immune response genes is one well-documented 
molecular feature of CLBCs [12, 49, 51, 103]. While these gene expression patterns may 
represent cancer cell-intrinsic features, they also reflect the presence of a wide array of 
infiltrating leukocytes, particularly pro-inflammatory macrophages. Due to associations 
among CLBC, inflammation, and macrophage energy metabolism [26, 100, 101, 104, 179, 
182, 183, 198-200], we used a pre-clinical model to determine whether suppression of 
myeloid cell glucose metabolism modulated CLBC progression and immunologic features of 
the tumor microenvironment linked to breast cancer.  
Previous cell-based assays in our laboratory have shown that Glut1 expression and 
glucose utilization are intimately tied to macrophage pro-inflammatory character [182]. 
Herein, we built upon our previous data by describing relationships between myeloid Glut1 
and the regulation of inflammation in vivo. This whole-animal context is important because it 
demonstrates that myeloid Glut1 regulates tissue-level inflammation with functional 
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implications for disease. Although our study did not identify specific mechanisms by which 
myeloid Glut1 represses CLBC progression, our data offer several clues. First, chronic 
inflammation per se is growth-permissive, but we did not observe genotype-driven 
differences in tumor Ki67 expression. Second, both Glut1M-/- BMDMs [183] and MTMs 
express lower levels of oxidative stress markers (e.g., iNOS/Nos2), so the reactive oxygen 
species burden associated with chronic inflammation may be relatively lower in Glut1M-/- 
tissues. Third, upregulation of APC markers (Cd80 and Cd86) in Glut1M-/- relative to 
Glut1MFl/Fl cancers may indicate a direct role for myeloid Glut1 in the control of tumor 
immune tolerance [201, 202]. Future studies should more closely examine the potential role 
of myeloid Glut1 in the regulation of tumor immunogenicity. 
Our data suggest that Glut1M-/- macrophages are skewed toward an anti-
inflammatory phenotype, but are associated with attenuated tumor progression. This pattern 
contrasts sharply with much of the available literature pertaining to TAM biology. Although 
little research has characterized the metabolic properties of TAMs, many studies have 
indicated that TAMs in advanced tumors possess anti-inflammatory character, and are 
therefore likely to exhibit an oxidative, rather than a glycolytic, metabolic signature [203]. 
TAMs have also been widely demonstrated to facilitate tumor progression, mediate 
development of therapeutic resistance, and promote relapse [203]. However, one recent 
study [204] found that macrophages exposed to secretions from pancreatic ductal 
adenocarcinoma cells (PDAC-TAMs) exhibited a pronounced glycolytic signature. PDAC-
TAMs also promoted tumor behaviors associated with invasion and metastasis, but these 
phenotypes were blocked upon inhibition of TAM glycolysis. This study [204] provided the 
first direct evidence that alterations in macrophage metabolism could promote cancer cell 
metastasis, and that reduced macrophage glycolysis – a previously reported feature of 
Glut1M-/- BMDMs [183] – could suppress metastatic spread. Although the CLBC cells used in 
the present study only invade locally, macrophage glycolysis-dependent tumor metastasis 
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may be applicable to this tumor type. Future work should establish whether CLBC-
associated TAMs also exhibit a glycolytic signature, and if inhibition of glycolysis in 
metastatic TNBC can prevent tumor cell dissemination. 
An additional intriguing finding of the present study is that myeloid Glut1 regulated 
the inflammatory character of normal mammary macrophages. To our knowledge, our study 
is the first to characterize specific immunophenotypes of MTMs; hence elucidating specific 
functions of individual MTM populations identified herein is an important area of future 
research. We were interested to observe a significantly increased proportion of MHCIIhi 
MTMs in Glut1M-/- relative to Glut1MFl/Fl mice, as MHCII expression in tumor immune cells 
inversely correlates with cancer progression [205-209]. Accordingly, our study could be 
strengthened by immunophenotypic analyses of TAMs in Glut1M-/- vs. Glut1MFl/Fl CLBCs.  
Although Glut1 expression in myeloid lineage neutrophils and dendritic cells is also 
targeted by LysM-Cre-mediated excision in our mouse model [210], we primarily focused our 
studies on macrophages because they are the most prevalent immune cell type in both 
normal and tumor mammary tissue, and play crucial roles in all phases of breast cancer 
development [25, 100]. Nevertheless, ongoing experiments in M-Wnt tumor tissue are 
further exploring how other myeloid cell types may contribute to the Glut1-dependent cancer 
progression phenotype. Ultimately, our study underscores a need to comprehensively 
evaluate the role of the tumor immune microenvironment in CLBC progression, and to 





Figure 3.1. Study schematic 
 
 
Study design. Mice were fed a purified diet at weaning and were orthotopically injected with 
M-Wnt CLBC cells at 13 weeks of age. Contralateral mammary and tumor tissues were 
harvested at tumor maximum size (1 cm in the largest dimension). Body weights were 













































Figure 3.3. Myeloid Glut1 deletion reduced MTM iNOS expression 
 
 
A) Distribution of ARG1 and iNOS expression among total mammary tissue macrophages 
(MTMs). B) Distribution of CD64 and MHCII expression among myeloid cells. C) Distribution 
of ARG1 and iNOS expression among CD64+MHCIIlo/- MTMs. D) ARG1 and iNOS MFIs 
among CD64+MHCIIlo/- MTMs. For all graphs, *p<0.05; **p<0.01, ***p<0.001. Exact 
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Figure 3.4. Histologic features of M-Wnt tumors 
 
 
A) Representative tumor H&E staining. Scale bar = 300 μm. B) Representative images and 
digital quantitation of tumor CD31 staining. Scale bar = 100 μm. C) Representative images 
and digital quantitation of Ki67 staining. Scale bar = 100 μm. D) Top: Representative images 
of tumor cleaved caspase-3 (CC3) staining. Arrowheads indicate “strong CC3-positive” 
apoptotic cells with a rounded-up morphology. Scale bar = 100 μm. Bottom: Positive pixel 
count algorithm output. Only “strong positive” staining (red), corresponding to apoptotic cells 
in top panels (arrowheads), was quantitated. Scale bar = 100 μm. Right: Digital 






































































Figure 3.5. Myeloid-specific Glut1 knockout delays tumor growth 
 
A) Analysis of tumor growth over time. Tumors were palpated three times weekly and 
tracked to a pre-determined size cutoff (1 cm in the largest dimension). B) Kaplan-Meier 
analysis showing that M-Wnt tumor growth to 1 cm progressed significantly more slowly in 
Glut1M-/- compared to Glut1


















Figure 3.6. Glut1M-/- immune microenvironments may suppress tumor growth 
 
A-D) Protein concentrations of the inflammatory cytokines MCP1 (**p=0.0064), IL-12β 
(*p=0.0171), TNFα (**p=0.0050), and IL-10 (***p=0.0003) in tumor lysates were quantitated 
with Luminex assays. E) Representative images and digital quantitation of tumor F4/80 





































































































































Table 3.1: Antibodies used for flow cytometry studies 
 
Antigen Fluorophore Company; cat. # Dilution Lot # 
Fc block 
(CD16/32) 
N/A Biolegend; 101320 1:50 B200134 
















MHC II BV711 
eBioscience; 


































Table 3.2: Antibodies and analysis parameters for quantitative histology 
 















1: 250 ZA0731 
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DEVELOPMENT OF A DIGITAL ALGORITHM TO QUANTITATE CD31+ VASCULATURE 






Studies of histologically benign-appearing, cancer-adjacent tissue may yield 
important insights into factors that influence locoregional disease recurrence after therapy. 
Triple-negative breast cancers are more likely than other breast cancer subtypes to recur 
locally and to metastasize within the first three to five years of patient follow-up, but 
microenvironmental factors underlying differential recurrence rates among breast cancer 
subtypes are poorly understood. Given the essential nature of tumor angiogenesis in cancer 
invasion and metastatic progression, we hypothesized that the vascular content of cancer-
adjacent breast tissue differs in association with the subtype of the corresponding tumor. To 
this end, we developed a novel digital algorithm to quantitate CD31+ vasculature in 
histologically benign tissue from women with breast cancer. We found that the digital 
algorithm was highly correlated with manual assessment, suggesting that high-throughput, 
quantitative estimates of vascular content and phenotypes could be provided.  This 
algorithm will ultimately be used to determine how parameters such as vascular density and 
median vessel size vary with respect to tumor subtype, established breast cancer risk 







Triple-negative breast cancer (TNBC) exhibits higher rates of locoregional 
recurrence relative to other breast cancer subtypes, particularly within the first three to five 
years of follow-up [52, 53, 57, 58]. Tumor biological characteristics are a key factor that may 
contribute to observed differential recurrence rates, but we and others have demonstrated 
that gene expression profiles of and cell-cell interactions within cancer-adjacent breast also 
vary according to the subtype of the corresponding tumor [76, 77]. For example, fibroblasts 
are key contributors to the inflammatory gene expression and cytokine production 
associated with TNBC-adjacent tissue environments [76]; however, it is unknown whether 
the content and/or phenotypes of other stromal cell types in benign-appearing, cancer-
adjacent tissue also differ in association with breast cancer subtype.  
The vasculature is a particularly understudied component of the breast cancer 
microenvironment. A small number of reports [111-114] have profiled cancer cell-endothelial 
interactions in the setting of frank breast tumors, but very little work has examined the 
vascular properties of normal or tumor-adjacent breast. Given that the induction of 
angiogenesis is a requisite step for progression to metastatic disease, it is plausible that 
subtype-specific differences in cancer-adjacent vascular properties may play a role in 
observed variations in local recurrence rates. We hypothesized that cancer-adjacent 
vascular content and phenotypes differ in association with the intrinsic subtype of the 
corresponding tumor. To this end, we developed a novel digital algorithm designed to 
quantitate immunohistochemical (IHC) staining of CD31, a cell-surface marker greatly 
enriched in endothelial cells, in histologically benign tissue from women with breast cancer. 
This algorithm will be used to determine how vascular features in cancer-adjacent tissue 
relate to tumor subtype, established breast cancer risk factors, and other histologic features 
of cancer-adjacent breast.  
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4.3. Materials and methods 
  
4.3.1. Study population  
 A subset of patients from the University of North Carolina Normal Breast Study (UNC 
NBS), a study previously described [211, 212], was included in this report. Briefly, the UNC 
NBS is a hospital-based study of normal breast tissue and breast cancer microenvironments 
conducted in association with UNC Hospitals. Women undergoing breast surgeries 
(excisional biopsy, lumpectomy, mastectomy, reduction mammoplasty, or other cosmetic 
procedure) between October 2009 and April 2013 were eligible to participate if they were at 
least 18 years of age, English-speaking, and consented to donate tissue during their 
surgery. As described in [211, 212], all participants donated grossly normal-appearing tissue 
as assessed by pathology assistants at UNC. Tissue was snap-frozen in liquid nitrogen. 
Patients also provided demographic, lifestyle, and breast cancer risk factor exposure data 
through a telephone interview, and medical records abstraction was performed to obtain 
anthropometric and medical history data. Medical records follow-up is continuing, to be 
conducted annually for 10 years following a patient’s surgery. Protocols were approved by 
the University of North Carolina School of Medicine Institutional Review Board. 
 The full UNC NBS study population consisted of 474 women, including 399 women 
with ipsilateral invasive breast cancer and 75 women with a benign breast condition [211]. 
Hematoxylin and eosin-stained tissue slides were created for each patient and manually 
reviewed. Specimens from 16 women were excessively folded and unsuitable for further 
analysis, whereas those from 4 women were found to have histologically abnormal tissue 
with >50% epithelial cell content. After excluding these 20 patients, the final NBS study 
population consisted of 454 women, including 387 women with ipsilateral invasive breast 
cancer and 67 women with a benign condition [211]. In the present analysis, cases with 
pathologically confirmed invasive, in situ, or benign breast disease, as well as those with a 
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prior history of breast cancer, were selected, excluding women undergoing prophylactic or 
cosmetic procedures. Since some participants in the NBS had a prior breast surgery, 
patients undergoing a second breast surgery were also excluded to avoid quantitating 
vasculature within granulation or fibrotic tissue induced by a previous breast surgery. These 
exclusions resulted in a total of 410 patients, of which 235 were randomly selected, equating 
to approximately half (51.8%) of all NBS study participants. We analyzed one sample per 
woman, using second specimens to assess intra-individual variation for approximately 20% 
of our population (n = 52 women; 22.1%). Slides were manually reviewed after IHC staining 
(see below), and 8 samples were excluded due to high levels of non-specific staining. 
Therefore, the total study population consisted of 228 women (50.2% of NBS participants) 
and 279 unique tissue samples. The demographic characteristics of our population are 
presented in Table 4.1. The majority of women in our study (91.7%) had invasive or in situ 
breast cancer at the time of their surgery, whereas the remaining patients had either a 
benign condition (7.5%) or a previous history of treated breast cancer at least one year prior 
to their consented surgery (0.9%). Average age at surgery was highest among breast 
cancer patients, and lowest among women presenting with benign conditions. Body mass 
index (BMI) did not differ substantially among groups.  
Given the high percentage of breast cancer patients in our study, the 
clinicopathologic characteristics of the corresponding tumors are presented in Table 4.2. 
Consistent with expectations, the majority of tumors were ER+, PR+, and HER2-. Tumors 
also tended to be small (<2.0 cm.) and low stage, with 85.2% of patients presenting with 
stage 0-2 disease. 
 
4.3.2. Immunohistochemical CD31 staining 
As described in [211], snap-frozen tissue was cut over dry ice and 20-μm sections 
were cut and mounted on positively charged glass slides. Slides were then randomized to 
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batches of 24, and IHC staining was performed according to standard protocols. Briefly, 
slides were fixed in zinc formalin for 10 minutes, and heat-induced epitope retrieval was 
performed using Lab Vision HIER Buffer (Thermo Fisher Scientific, Waltham, MA). Slides 
were then incubated with 3% hydrogen peroxide to block endogenous peroxidases, blocked 
with 10% normal goat serum for 1 hour at room temperature, and incubated with pre-titrated 
mouse anti-CD31 antibodies (0.25 μg/mL; #3528, lot #4; Cell Signaling Technologies, 
Danvers, MA) overnight at 4°C. Slides were then incubated with biotinylated goat anti-
mouse IgG secondary antibodies (#115-065-166, lot #89998; Jackson ImmunoResearch, 
West Grove, PA) for 1 hour at room temperature, and staining was visualized using ABC 
Elite (#PK-6100; Vector Laboratories, Burlingame, CA) and diaminobenzidine (DAB; #TA-
125-QHDX; Thermo Fisher Scientific) reagents. Antibodies were diluted in Thermo Antibody 
diluent (#TA-125-ADQ), and all washes were performed with 0.05M Tris + 0.05% TWEEN-
20. All sections were counterstained with hematoxylin. 
A negative control (no-primary antibody) slide consisting of human umbilical vein 
endothelial cells (HUVECs) grown on chamber slides was included in each batch of stained 
breast tissue to control for non-specific binding of the secondary antibody. HUVECs (ATCC, 
Manassas, VA) maintained in EGM-2 culture medium supplemented with BulletKit reagents 
(Lonza, Walkersville, MD) were seeded at a density of 50,000 cells/well in 1 well of a 4-well 
chamber slide (BD Falcon, Franklin Lakes, NJ), and permitted to grow for 3 days. Slides 
were then fixed with 4% paraformaldehyde, and stained (1 slide per batch of tissue) 
according to the protocol described above.  
 
4.3.3. Development of digital algorithm 
Stained slides were scanned into high-resolution digital images using the Aperio 
ScanScope CS system (Aperio Technologies, Vista, CA) at a magnification of 20x. Tissue 
aberrations (e.g., large folds, surgical ink) and areas of extensive non-specific staining were 
 
 80 
excluded via annotation with Aperio ImageScope software. All annotations were made by an 
investigator blinded to patient demographic information and other tissue characteristics. 
Annotated images were then imported into Definiens Architect XD version 2.7.0 for analysis 
with Definiens Tissue Studio version 4.4.2 (Cambridge, MA). Briefly, a training set consisting 
of 30 randomly selected slides was constructed, and the tissue and glass components of 
each specimen were segmented (Figure 4.1A-B). A Tissue Studio Cellular Analysis 
Solution capable of detecting and classifying IHC-stained vasculature was then tuned to 
identify DAB+ (i.e., CD31+) regions. Importantly, given reports that capillaries average 8 μm 
in diameter [213], we trained the algorithm to exclude stained objects with cross-sectional 
areas of <50 μm2. High-magnification views of the tissue area outlined in Figure 4.1A are 
shown in Figures 4.1C-E to illustrate vascular detection. The algorithm first detects “entire” 
blood vessels without regard to underlying vascular structure, which can be classified 
according to user-defined or software-default size categories if desired (Figure 4.1D). The 
algorithm then partitions each vascular object into “wall” and “lumen” components as 
applicable (Figure 4.1E).  
 
4.3.4. Algorithm validation 
After the trained algorithm was applied to the entire slide set, digital images were 
manually reviewed for gross irregularities. Visual inspection suggested high accuracy in 
identifying vascular areas. However, we identified 75, predominantly stroma-rich and mixed-
histology slides with faint staining for which the tissue and glass components were not 
reliably partitioned. Thus, the tissue vs. glass parameter was re-tuned for this subset of 
slides, leaving all vascular parameters unchanged. However, misclassification persisted in 
42.7% of slides from this subset (11.5% of all study specimens), and deficits in vessel 
quantitation were detected during validation (see below; data not shown). Therefore, the 
original algorithm was utilized for all 279 slides, and future molecular epidemiologic 
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assessment of vessel histology will incorporate sensitivity analyses excluding these 75 
slides with areas of problematic classification. 
Vessel density and average vessel size were computed by the algorithm in an 
automated fashion. Custom SAS software scripts (version 9.4; SAS Institute, Cary, NC) 




100), and percent endothelial area (
total vessel area - lumen area
tissue area
 * 100) using data exported from 
Definiens Tissue Studio “Image Object Tables,” which contain quantitative data 
corresponding to every stained object in a given slide. Data obtained from these automated 
approaches were compared to results acquired from manual slide annotation. A validation 
set consisting of 33 randomly selected slides with 1-2 serial sections each was constructed 
and each slide was manually annotated at high magnification using Aperio ImageScope 
software, with each annotation layer representing a different tissue component (Figure 4.2). 
Only structures with 2 or more nuclei were annotated to minimize the inclusion of CD31+ 
leukocytes, and structures with cross-sectional areas of <50 μm2 were excluded to facilitate 
agreement with the algorithm. Vessel density (
number of vessels
net tissue area
), median vessel area, average 
vessel area, percent vessel area (
total vessel area
net tissue area
 * 100), and percent endothelial area 
(
total vessel area - lumen area
net tissue area
 * 100) were then computed for each slide, with net tissue area 
equivalent to tissue area - (glass area + artifacts area) for all metrics. The agreement 
between automated and manually calculated values was evaluated with Pearson’s 
correlation, percentage agreement, and Cohen’s quadratic weighted kappa analyses using 








4.4.1. Evaluation of algorithm performance: comparison to manual annotation  
To evaluate algorithm performance, we first conducted correlation analyses wherein 
automated data from 33 randomly selected slides was compared to that acquired from 
manual annotation. Correlation analyses for each vascularity metric, as well as tissue area, 
are presented in Figures 4.3. Automated and manually derived tissue areas were strongly 
correlated (Pearson’s correlation coefficient, r = 0.8936) despite the presence of tissue-glass 
misclassifications in 15.2% (5/33) of slides in the validation set (Figure 4.3A). In addition, 
moderate associations were observed between automated and manually computed vessel 
density (r = 0.5559), median vessel size (r = 0.4894), and average vessel size (r = 0.5626) 
(Figure 4.3B-D). Automated and manually derived percent vascular area (r = 0.2697) and 
percent endothelial area (r = 0.2397) were weakly correlated (data not shown) and will be 
excluded from future studies. Moreover, the dynamic range of these latter parameters was 
generally limited (range: 0-4), indicating that they are unlikely to be biologically meaningful.  
To explore possible explanations for the observed variability between automated and 
manually computed vascular metrics, we considered that algorithm performance may vary in 
association with tissue histology and classified each slide in the validation set as “fibrous,” 
“fatty,” or “mixed”. However, these adjustments for tissue composition did not uniformly 
improve overall agreement between automated and manually calculated vascularity metrics 
(data not shown). 
We further assessed algorithm performance by dividing the automated and manual 
measurements for each vascular metric (vessel density, and median and average vessel 
size) into quartiles, and calculating the percent agreement between quartile assignments 
(Tables 4.3-4.5). When perfect agreement was required (grey cells in Tables 4.3-4.5), the 
percent agreement between automated and manual metrics equaled 48.5% for all 3 
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vascular parameters. Due to the heterogeneity of our datasets, we then calculated percent 
agreement after dichotomizing the data for each metric above and below the median (thick 
cell outlines in Tables 4.3-4.5). Percent agreement between quartile assignments increased 
to 70.0% for vessel density (quadratic-weighted Cohen’s κ: 0.4748), and to 75.8% for both 
median and average vessel size (quadratic-weighted Cohen’s κ: 0.4878 and 0.5022, 
respectively). 
 
4.4.2. Distributions of tissue vascularity metrics 
Having gained a comprehensive understanding of algorithm performance vs. manual 
annotation, we sought to characterize the biologic variability of each metric across the entire 
study slide set (n = 279 specimens). Histograms depicting the distribution of each metric are 
presented in Figure 4.4. The vessel density distribution exhibited a leftward skew, with the 
majority of data points residing between 0 and 125 vessels/mm2 (Figure 4.4A). Data 
pertaining to median vessel size approximated a normal distribution (Figure 4.4B); however, 
that of average vessel size exhibited a leftward skew and substantially larger range (~100-
700 μm2 [average] vs. 75-150 μm2 [median]; Figure 4.4C). We also plotted the distribution of 
percent vessel area and percent endothelial area, and confirmed the limited dynamic range 





A small number of previous studies [116, 117] has characterized the vascular 
features of normal breast tissue. However, these studies only reported data from a small or 
unspecified number of women, and one study [117] only consented women aged 18-29 
years. Therefore, little is known about: 1) whether vascular characteristics of normal human 
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breast tissue vary in association with diverse demographic factors; and 2) how the vascular 
features of histologically normal tissue adjacent to breast cancers may vary in accordance 
with corresponding tumor subtypes and in association with established breast cancer risk 
factors. To address these knowledge gaps, we generated a novel, high-throughput algorithm 
tuned to quantitate CD31+ vasculature in histologically normal breast tissue from women 
with breast cancer. This algorithm was applied to a set of 279 specimens from 228 women, 
and, to our knowledge, represents the largest, most comprehensive analysis of normal 
breast vascular content reported to-date.  
Our method was developed via integration of high-throughput digital technology and 
manual review. First, prior to tuning the algorithm, we minimized the inclusion of tissue 
aberrations and artifacts with potential to substantially misrepresent vascular content and 
phenotypes. In the second cycle of manual review, performed after applying the algorithm to 
all 279 specimens, we examined each digitally annotated slide for gross irregularities. 
Finally, automated and manually computed vessel parameters were directly compared. 
Evaluation of vascular characteristics in the 33-slide validation set revealed that, compared 
to manual annotation, the algorithm tended to overestimate vessel density and 
underestimate both median and average vessel size. However, these estimates were 
quantitatively highly correlated with the manual estimates and can be objectively and 
reproducibly estimated, and visual inspection suggested high accuracy in identifying 
vascular regions. The observed discrepancies appeared to primarily arise from the inability 
of the algorithm to discern objects with staining intensities below a certain threshold. Large 
vessels, particularly those sectioned in an oblique fashion, exhibited areas of faint and/or 
non-continuous endothelial cell staining and were partitioned by the algorithm into multiple 
smaller structures. In contrast, overarching vessel structure was more faithfully captured 
during manual annotation, leading to relative reductions in vessel density and increases in 
vessel size. Despite these differences, automated and manually computed parameters 
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exhibited moderate concordance according to widely accepted benchmarks for 
interpretation of the Cohen’s κ statistic [214]. Nevertheless, future molecular epidemiologic 
assessment of this dataset (see below) will include sensitivity analyses excluding samples 
with areas of problematic classification.  
The data obtained from this method will be applied in the context of a molecular 
epidemiologic study to characterize vascular content (vessel density) and phenotypes 
(median vessel size) in cancer-adjacent normal breast. Median, as opposed to average, 
vessel size was selected for use in future analyses because the data for this parameter 
across all study specimens approached a normal distribution. Samples from NBS are well 
annotated with respect to clinical features and patient demographic data, enabling studies of 
how vascular features vary with the intrinsic subtype of the corresponding tumor, as well as 
in association with tissue histology and established breast cancer risk factors. Ultimately, we 
anticipate that this work will reveal subtype-specific differences in the vascular properties of 
cancer-adjacent breast, and provide insight into factors that may contribute to observed 




Figure 4.1. Example of vascular algorithm output 
 
 
A) Histologic section of adipose-rich cancer-adjacent breast immunohistochemically stained 
for CD31. The black rectangle indicates the location presented at high magnification in C-E. 
Scale bar = 500 μm. B) Digital rendering of tissue (blue) vs. glass (grey) components. Scale 
bar = 500 μm. C) High-magnification image of the location outlined in A. Brown indicates 
areas of CD31-positivity. D) Digital rendering of vessel identification algorithm; in this output, 
no distinction is made between vessel lumena and walls. Vessel size categories (e.g., 
medium [orange]; large [red]) are shown here for illustration purposes only. E. Digital 
rendering of vessel identification algorithm; this output can distinguish between vessel walls 
(purple) and vessel lumena (green). Scale bar for C-E = 50 μm. 
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Digital images of adipose- (top) and stroma-rich (bottom) tissue specimens overlaid with the 
layers denoting the algorithm analysis area (green layer) and manually segmented tissue 
compartments. The blue, magenta, red, and yellow layers denote manually annotated tissue 
area, glass and artifacts, vessels, and vessel lumina, respectively. In the top slide, air 
bubbles outlined in dashed green lines (indicated with arrows) were excluded from the 
algorithm analysis area. Scale bar for both panels  = 3 mm. 
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Figure 4.3. Correlations between automated and manually computed vessel metrics 
across the 33-slide validation set 
 
 
Pearson’s correlation coefficients and lines of best fit comparing automated and manually 
computed tissue and vascular parameters for the 33-slide validation set, including A) tissue 










r = 0.8936 r = 0.5559 
r = 0.4894 
C) D) 
r = 0.5626 
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Distribution (sample proportion and count) of A) vessel density (1/mm2 of tissue), B) median 


















Table 4.1. Distribution of patient demographic factors (n = 228) 
 
 
















     
Total n (%) 180 (78.9) 2 (0.9) 29 (12.7) 17 (7.5) 
     
Age at surgery + SD 53.8 + 12.3 49.5 + 7.7 57.3 + 12.0 46.7 + 15.4 
     
Race     
    White 110 (61.1) 2 (100.0) 21 (72.4) 9 (52.9) 
    Black 56 (31.1) 0 (0.0) 3 (10.3) 7 (41.2) 
    Other/Not reported 14 (7.8) 0 (0.0) 5 (17.2) 1 (5.9) 
     
BMI + SD (kg/m2)  29.4 + 6.9 33.8 + 7.7 25.7 + 5.7 28.4 + 8.3 
 
*Patients with a prior breast cancer history were diagnosed and treated with complete 
response at least one year prior to the consented surgery, and had no active disease at the 









   
Stage   
    0 29 13.9 
    1 93 44.5 
    2 56 26.8 
    3 22 10.5 
    4 6 2.9 
    Missing 3 1.4 
   
Grade   
    1 40 19.1 
    2 81 38.8 
    3 85 40.7 
    Missing 3 1.4 
   
Tumor size   
    <2 cm. 113 54.1 
    >2-5 cm. 68 32.5 
    >5 cm. 28 13.4 
   
Lymph node status   
    Positive 70 33.5 
    Negative 116 55.5 
    Missing 23 11.0 
   
ER status   
    Positive 146 69.9 
    Borderline 4 1.9 
    Negative 54 25.8 
    Missing 5 2.4 
   
PR status   
    Positive 121 57.9 
    Borderline 6 2.9 
    Negative 76 36.4 
    Missing 6 2.9 
   
HER2 status*   
    Positive 34 18.9 
    Negative 138 76.7 
    Missing 8 4.4 
 
*Among invasive cases only. 
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Table 4.3. Agreement between automated and manually computed vessel density in 
the 33-slide validation set  
 
 Automated 
Q1 Q2 Q3 Q4 Totals 
Manual 
Q1 4 3 2 0 9 
Q2 2 3 0 3 8 
Q3 3 1 4 0 8 
Q4 0 1 2 5 8 
Totals 9 8 8 8  
 
Quadratic-weighted Cohen’s κ: 0.4748 (95% CI: 0.1738 - 0.7830) 
 
Percent agreement (perfect agreement): 48.5% 
 
Percent agreement (dichotomization above and below the mean): 70.0% 
 
Q: quartile; CI: confidence interval. Shaded cells indicate perfect agreement between 
automated and manually calculated metrics, whereas cells outlined with thick gridlines 

































Table 4.4. Agreement between automated and manually computed median vessel size 
in the 33-slide validation set  
 
 Automated 
Q1 Q2 Q3 Q4 Totals 
Manual 
Q1 5 2 2 0 9 
Q2 2 4 1 1 8 
Q3 2 0 3 3 8 
Q4 0 2 2 4 8 
Totals 9 8 8 8  
 
Quadratic-weighted κ: 0.4878 (95% CI: 0.1832 - 0.7924) 
 
Percent agreement (perfect agreement): 48.5% 
 
Percent agreement (dichotomization above and below the mean): 75.8% 
 
Q: quartile; CI: confidence interval. Shaded cells indicate perfect agreement between 
automated and manually calculated metrics, whereas cells outlined with thick gridlines 
































Table 4.5. Agreement between automated and manually computed average vessel 
size in the 33-slide validation set  
 
 Automated 
Q1 Q2 Q3 Q4 Totals 
Manual 
Q1 5 3 0 1 9 
Q2 2 3 3 0 8 
Q3 1 0 4 3 8 
Q4 1 2 1 4 8 
Totals 9 8 8 8  
 
Quadratic-weighted κ: 0.5022 (95% CI: 0.1960 - 0.8084) 
 
Percent agreement (perfect agreement): 48.5% 
 
Percent agreement (dichotomization above and below the mean): 75.8% 
 
Q: quartile; CI: confidence interval. Shaded cells indicate perfect agreement between 
automated and manually calculated metrics, whereas cells outlined with thick gridlines 



















With a focus on characterizing the unique features of TNBC microenvironments, this 
body of work laid a strong, broad foundation for understanding how breast tissue stroma 
varies in association with the intrinsic subtype of the corresponding tumor. Our studies 
highlight the complexity of TNBC microenvironments by profiling three distinct stromal cell 
constituents (fibroblasts, myeloid cells, and vasculature), and have relevance to multiple 
stages of disease (pre-malignant, invasive, and recurrent TNBC). In Chapter 2, profiling of 
cell-cell interactions in pre-malignant BBC revealed that fibroblasts induced p53-dependent 
morphologic changes in benign and atypical hyperplastic epithelium that correlated with 
distinct patterns of transcription. In Chapter 3, we demonstrated that suppression of 
glycolysis in myeloid cells impeded CLBC progression, potentially through the regulation of 
inflammation in both normal and tumor microenvironments. Finally, in Chapter 4, we 
developed a digital algorithm designed to quantitate CD31+ vasculature in histologically 
benign tissue from breast cancer patients, with the long-term goal of understanding how 
cancer-adjacent vascular content and phenotypes relate to differential recurrence rates 
among tumor subtypes. Collectively, this work addressed important questions relating to 
stromal-epithelial interactions in TNBC, identifying previously uncharacterized phenotypic, 
transcriptional, and proteomic responses of cancer cells to their microenvironments. 
Additional studies to uncover epidemiologic associations that directly relate to stromal-
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epithelial interactions in human tissue are also underway (see section 5.4). The goal of the 
present Chapter is to describe the overarching translational relevance of this dissertation, 
and to broadly demonstrate how the complementary experimental models used herein can 
be integrated in future work (Figure 5.1).  
 
 
5.2. Importance and translational implications of studying pre-invasive and malignant 
stromal-epithelial interactions  
 
The tissue microenvironment been described as a contextual double-edged sword.  
Physiologic microenvironments can restrain or even revert malignant phenotypes, whereas 
aberrant, permissive microenvironmental signals destabilize tissue architecture to promote 
carcinogenesis and malignant progression [59]. That the normal microenvironment acts as a 
barrier to carcinogenesis implies that tumorigenic cells must acquire, and that normal 
microenvironments select for, mutations and associated adaptive phenotypes (e.g., 
enhanced proliferation and/or invasion) that improve biologic fitness [215].  
Studies of heterotypic interactions during early stages of tumor development are 
important for understanding how pre-malignant cells overcome microenvironmental 
constraints. In Chapter 2, we characterized the evolution of stromal-epithelial interactions 
during progression to malignancy and identified novel morphogenetic responses of pre-
invasive breast epithelium to fibroblast co-culture. Responses to co-culture were dependent 
upon genetic context (i.e., epithelial p53 status), with p53-deficient cells displaying 
accelerated adaptive changes (increased asphericity/local invasion) relative to p53-sufficient 
controls. Furthermore, identification of gene expression patterns correlating with morphology 
provides insight into signals that induce or sustain adaptive epithelial phenotypes, and may 
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lead to the identification of targetable interactions for BBC prevention in susceptible 
populations.  
Invasive cancer cells possess an array of adaptive phenotypes that have enabled 
them to successfully overcome stromal barriers to carcinogenesis. In turn, aberrant 
paracrine communication patterns between cancer cells and the surrounding tissue facilitate 
development of a permissive stroma that further perpetuates tumor progression [215]. 
Elucidation of stromal-epithelial interactions in established TNBCs, such as those described 
in Chapter 3, is crucial for the development of novel therapeutic targets for this clinically 
intractable tumor subtype. Similarly, although the M-Wnt cells used in our study only invade 
locally within the mammary fat pad, studies of heterotypic interactions can also provide 
important insights into the biology of metastatic tumors: identification of stromal factors that 
retain metastatic cancer cells in a latent state, as well as signals enabling them to emerge 
from dormancy, will be crucial for preventing disease relapse [59, 216, 217]. Whether or not 




5.3. Limitations  
 
5.3.1. 3D cultures  
Although 3D co-cultures facilitate contextually relevant studies of tissue biology, 
particularly compared to cells cultured in a monolayer on plastic, the inclusion of a limited 
number of cell types (e.g., cancer cells and one stromal cell constituent) implies that these 
models fail to recapitulate the full dynamic complexity of living tissues. Similarly, we also 
acknowledge that immortalized stromal cells, such as the hTERT-immortalized fibroblasts 
used herein, do not reflect the full spectrum of biologic variability associated with primary 
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human cells. Primary fibroblasts from each stage of pre-malignant breast disease 
represented in our study would offer the greatest degree of physiologic relevance; however, 
tissue of suitable quality for live-cell isolation is not readily available. Thus, co-cultures are 
amenable to the study of a single or small number of signaling pathways in relative isolation 
and under relatively homogeneous conditions, but more complex model systems and related 
analytical approaches are required to understand how cell-cell interactions are altered in 
more heterogeneous environments. While OCT may be technically amenable to analyses of 
this nature, the non-high-throughput nature and complex technologic requirements of this 
method currently preclude its widespread use in the field. Therefore, development of more 
streamlined OCT analysis procedures and novel bioinformatic tools for increasingly complex 
models of TNBC microenvironments is critical. 
 
5.3.2. Orthotopic tumor model 
A limitation of orthotopic tumor models in general is that the natural history of these 
cancers is substantially different from that of human disease. Injection of mice with tumor 
cells represents an “artificial” etiology, whereas human carcinogenesis occurs in part due to 
genetic predisposition and/or acquisition of somatic mutations from environmental 
exposures. Orthotopic models also typically require greater technical skill, particularly 
compared to subcutaneous models, as cells must be precisely injected or even surgically 
implanted into the desired tissue [218]. Despite these limitations, orthotopic models afford 
many advantages to studies of tumor microenvironments, including: 1) the ability to inject 
the same number of cancer cells into each animal, thus enabling experimental control; 2) 
relatively rapid tumor development (typically days to weeks vs. weeks to months for 
spontaneous cancer models); and 3) physiologic relevance with respect to site of tumor 




Given that CLBC was only recently recognized [48], there is an urgent need to better 
characterize the mutational profiles of human cancers to enable more physiologically 
relevant studies of tumor-stromal interactions, particularly in in vivo settings. Previous 
studies in animal models suggest that loss-of-function mutations in TP53 may be important 
in the biology of this subtype. For example, Knight et al. recently reported a GEMM of 
spontaneous breast cancer wherein both cMET overexpression and p53 loss in the 
mammary epithelium synergize to promote tumors that pathologically resemble human 
CLBCs [75]. In addition, overexpression of prolactin in the mammary epithelium of TP53-null 
mice accelerated the formation of tumors with claudin-low histopathology [219]. However, as 
the M-Wnt cells used in Chapter 3 are TP53-wild-type, additional genetic factors are likely to 
play a role in CLBC development and progression. Data pertaining to BBCs may provide 
additional clues; however, we must caution that the documented molecular differences 
between BBCs and CLBCs [12, 49, 51] imply that results from studies of one subtype may 
not be broadly applicable to the other.  
 
5.3.3. Human tissue model 
Results from the NBS must be interpreted in light of its hospital-based nature. 
Participants are more likely to reflect the population of Chapel Hill, NC and surrounding 
areas, with overall higher socioeconomic status and better access to healthcare than the 
general US population. However, given the limited number of previous studies pertaining to 
normal and cancer-adjacent breast vasculature, as well as the qualitative nature thereof and 
small number of patients therein, our study is an important step to understanding how 
tumor-adjacent vasculature varies in association with tumor subtype and associated risk 
factors. Nevertheless, it will be important to validate our results in additional populations. We 
must also acknowledge that a general limitation of digital histology algorithms is that they 
must often be tuned to individual slide sets due to variability in tissue preservation methods 
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(frozen vs. FFPE), tissue topologies, colorimetric substrates, and staining intensities, 
potentially precluding their use in clinical settings where rapid specimen assessment is 
required. Furthermore, algorithms also exhibit limited flexibility and analyses are bound by a 
finite set of parameters. To circumvent these constraints, novel machine/deep learning 
modalities are being developed for a variety of biologic applications, including using digital 
histology images to diagnose, subtype, and prognose breast cancers [220-223]. Ultimately, 
there is much to be learned from molecular research of human tissue, to which 




5.4. Avenues for future research: methodologic complementarity 
 
A natural extension of the work presented in Chapter 2 is to characterize p53-
dependent fibroblast-epithelial interactions in the context of malignant BBC. To this end, 
similar 3D morphogenesis and gene expression assays to those described herein are 
currently ongoing, leveraging a panel of well-characterized isogenic (p53-sufficient and -
deficient) invasive breast cancer cell lines. Incorporation of both BBC (HME-CC, SUM102) 
and luminal (MCF-7, ZR-75-1) cell line pairs in this study will also facilitate identification of 
subtype-specific microenvironmental interactions, as opposed to generalized, stereotypic 
responses of breast cancer cells to fibroblast co-culture. Interestingly, an invasive MCF10 
line (MCF10CA1a) with a spontaneous activating mutation in PIK3CA has also been 
reported [224], and creation of a p53-deficient line could enable investigations of malignant 
stromal-epithelial crosstalk on an otherwise isogenic background.  
Pathway-focused analyses of co-cultures can be further tested in the context of 
human studies. In particular, the rapid proliferation of publically available datasets facilitates 
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validation of gene signatures (specific groups of genes that vary in response to a given 
biologic stimulus) or other transcriptional findings in human patients at minimal cost. 
Integration of these techniques is critical for the identification and validation of novel risk 
factor, diagnostic, prognostic, and predictive biomarkers in breast cancer.  
The predominant question raised in Chapter 3 is mechanistic in nature: how 
precisely does loss of myeloid Glut1 impair CLBC progression? Our study points to a role for 
myeloid Glut1-mediated modulation of inflammatory processes, but these interactions must 
be further evaluated in a mechanistic setting. Integration of additional animal models and 
cell-based assays will have utility for exploring these novel hypotheses. As one example, to 
test the hypothesis that increased immunosurveillance (i.e., altered effector T cell function) 
underlies the delayed tumor progression observed in Glut1M-/- compared to Glut1MFl/Fl mice, 
Glut1M-/- animals could be crossed to syngeneic C57BL/6J Rag1 null mice; the resulting 
animals would harbor Glut1-/- myeloid cells and would lack mature T (and B) cells 
(https://www.jax.org/strain/002216). Normalization of M-Wnt tumor progression patterns in 
Glut1M-/-; Rag1-/- mice to Glut1MFl/Fl or near-Glut1MFl/Fl levels would implicate a role for Glut1-
dependent myeloid cell-T cell interactions in regulating CLBC progression. In vitro T cell-
stimulation assays could also be performed to test this hypothesis in the context of a smaller 
scale, more tractable experimental unit. Incubation of cytotoxic T-cells with tumor-associated 
macrophages from mice of both genotypes, followed by incubation of primed T-cells with 
cultured M-Wnt cells, could enable direct assessment of T cell cytotoxicity in the context of 
Glut1M-/- and Glut1MFl/Fl microenvironments. Importantly, however, these cell-based assays 
would necessitate extensive study of primary cell phenotypes to facilitate experimental 
reproducibility, as well as a careful evaluation of culture conditions to ensure primary cell 
survival for the duration of the assay. 
An additional area for future research with relevance to Chapter 3 relates to the 
concept of reverse Warburg metabolism. In this model, activated CAFs undergo Glut1-
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dependent aerobic glycolysis and secrete lactate into the tumor microenvironment, in turn 
“feeding” cancer cells and enabling cancer cell oxidative mitochondrial metabolism [225, 226]. 
This stromal-epithelial “lactate shuttle” has been reported to facilitate prostate tumor growth 
[227] and protect breast cancer cells from hypoxia-mediated apoptosis [226], and may 
underlie tumor-promoting effects of CAFs in colon cancer and melanoma models [228]. 
Evidence of the reverse Warburg effect has also been detected in human breast and prostate 
tumors, wherein it is associated with increased recurrence rates and high tumor stage, 
respectively [226, 229]. Interestingly, our laboratory has previously demonstrated that BMDMs 
from Glut1M-/- relative to Glut1MFl/Fl mice produce lower concentrations of lactate in response 
to pro-inflammatory lipopolysaccharide/interferon gamma (LPS/IFNγ) stimulation [183]. 
Accordingly, important avenues for future research are to determine if Glut1M-/- MFP 
macrophages also produce less lactate in response to pro-inflammatory stimuli, and to 
address whether macrophages in tumor stroma also contribute to the growth-promoting 
effects of reverse Warburg metabolism in cancer. 
Finally, as aforementioned, the algorithm described in Chapter 4 will be applied to 
molecular epidemiologic studies of human tissue. Samples in the NBS are clinically 
annotated with respect to both demographic and life exposure data, enabling thorough 
assessment of how vascular content and phenotypes vary in association with TNBC tumor 
characteristics (e.g., grade, stage, size, and lymph node status) and risk factors (e.g., young 
age/premenopausal status, African American race, obesity, parity, and never having 
breastfed) [19, 22, 31, 32, 41]. Furthermore, as molecular characteristics of frank breast 
tumors are strongly reflected in histologically normal tissue located within 1 cm of the 
primary lesion, but are attenuated or absent at distances of 3 and 5 cm [230-232], it will also 
be important to consider the distance of each cancer-adjacent tissue sample from the tumor.  
In future work, mechanisms by which the vasculature influences both primary and 
metastatic tumor behavior should be characterized. Animal tumor models will be particularly 
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important to contextualizing these studies to epidemiologic associations identified with the 
vascular algorithm, particularly those that are challenging or even impossible to model in 
cell-based systems (e.g., parity). Interactions identified in tissue-level studies can be further 
dissected in vitro, wherein utilization of breast-specific endothelial cells will be crucial to 
maintaining the physiologic relevance of the system [111, 112, 116]. 
In conclusion, the work presented herein used a broad range of molecular tools to 
identify novel phenotypic, transcriptional, and tissue-level responses of TNBC cells to a 
diverse array of microenvironmental constituents. Continued, integrated use of these 
complementary model systems is vital to further enhancing our understanding of stromal-
epithelial interactions in TNBC, and to conclusively identifying novel therapeutic targets for 































Figure 5.1. Integration of complementary model systems furthers knowledge of TNBC 
microenvironments 
 
A number of complementary model systems are available for the study of tissue 
microenvironments. Epidemiologic associations revealed by human studies can be 
mechanistically probed “in-context” with animal models, or in cell-based assays that afford a 
highly controlled setting. In vitro assays that identify novel stromal-epithelial communication 
patterns or improve mechanistic understanding of previously described interactions can be 
further examined in the setting of a complex living tissue, whereas tissue-level phenomena 
in animals can be dissected into smaller, more tractable experimental units in vitro. 
Moreover, hypothesis-generating work in animals can be supplemented by incorporating 
additional genetically engineered in vivo models that improve mechanistic understanding. 
Finally, results from studies of stromal-epithelial interactions in both cell-based and animal 
models can be applied in epidemiologic resources to determine the relevance of a given 
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